﻿<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN" "JATS-journalpublishing1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article">
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Explor Asthma Allergy</journal-id>
<journal-id journal-id-type="publisher-id">EAA</journal-id>
<journal-title-group>
<journal-title>Exploration of Asthma &amp; Allergy</journal-title>
</journal-title-group>
<issn pub-type="epub">2837-5076</issn>
<publisher>
<publisher-name>Open Exploration Publishing</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.37349/eaa.2024.00055</article-id>
<article-id pub-id-type="manuscript">100955</article-id>
<article-categories>
<subj-group>
<subject>Review</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>A practical guide to recognize allergic and immunologic skin diseases: diagnosis at first sight</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Cataudella</surname>
<given-names>Edoardo</given-names>
</name>
<role content-type="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role>
<role content-type="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role>
<role content-type="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role>
<role content-type="https://credit.niso.org/contributor-roles/supervision/">Supervision</role>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing—original draft</role>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing—review &amp; editing</role>
<xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref>
<xref ref-type="fn" rid="afn1">
<sup>†</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Perlato</surname>
<given-names>Margherita</given-names>
</name>
<xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref>
<xref ref-type="fn" rid="afn1">
<sup>†</sup>
</xref>
<xref ref-type="corresp" rid="cor1">
<sup>*</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Salvati</surname>
<given-names>Lorenzo</given-names>
</name>
<xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="I2">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Di Agosta</surname>
<given-names>Ester</given-names>
</name>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing—original draft</role>
<xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Romaldi</surname>
<given-names>Arianna</given-names>
</name>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing—original draft</role>
<xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Paolino</surname>
<given-names>Donato</given-names>
</name>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing—original draft</role>
<xref ref-type="aff" rid="I3">
<sup>3</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ambrogio</surname>
<given-names>Francesca</given-names>
</name>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing—original draft</role>
<xref ref-type="aff" rid="I4">
<sup>4</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Marietti</surname>
<given-names>Rossella</given-names>
</name>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing—original draft</role>
<xref ref-type="aff" rid="I5">
<sup>5</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Magistà</surname>
<given-names>Stefania</given-names>
</name>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing—original draft</role>
<xref ref-type="aff" rid="I3">
<sup>3</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Schettini</surname>
<given-names>Natale</given-names>
</name>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing—original draft</role>
<xref ref-type="aff" rid="I6">
<sup>6</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Tramontana</surname>
<given-names>Marta</given-names>
</name>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing—original draft</role>
<xref ref-type="aff" rid="I5">
<sup>5</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Bartolomeo</surname>
<given-names>Luca Di</given-names>
</name>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing—original draft</role>
<xref ref-type="aff" rid="I7">
<sup>7</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Passante</surname>
<given-names>Maria</given-names>
</name>
<xref ref-type="aff" rid="I8">
<sup>8</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Pino</surname>
<given-names>Marina Di</given-names>
</name>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing—original draft</role>
<xref ref-type="aff" rid="I9">
<sup>9</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Marco</surname>
<given-names>Aurora De</given-names>
</name>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing—original draft</role>
<xref ref-type="aff" rid="I4">
<sup>4</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Potestio</surname>
<given-names>Luca</given-names>
</name>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing—original draft</role>
<xref ref-type="aff" rid="I10">
<sup>10</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Angilieri</surname>
<given-names>Luisa</given-names>
</name>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing—original draft</role>
<xref ref-type="aff" rid="I11">
<sup>11</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Cannas</surname>
<given-names>Rossana</given-names>
</name>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing—original draft</role>
<xref ref-type="aff" rid="I12">
<sup>12</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Mormile</surname>
<given-names>Ilaria</given-names>
</name>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing—original draft</role>
<xref ref-type="aff" rid="I13">
<sup>13</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Trave</surname>
<given-names>Ilaria</given-names>
</name>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing—original draft</role>
<xref ref-type="aff" rid="I14">
<sup>14</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Conte</surname>
<given-names>Maria Elisabetta</given-names>
</name>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing—original draft</role>
<xref ref-type="aff" rid="I15">
<sup>15</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ferrucci</surname>
<given-names>Silvia</given-names>
</name>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing—original draft</role>
<xref ref-type="aff" rid="I11">
<sup>11</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Gallo</surname>
<given-names>Rosella</given-names>
</name>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing—original draft</role>
<xref ref-type="aff" rid="I14">
<sup>14</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zancanaro</surname>
<given-names>Andrea</given-names>
</name>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing—original draft</role>
<xref ref-type="aff" rid="I16">
<sup>16</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Boni</surname>
<given-names>Elisa</given-names>
</name>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing—original draft</role>
<xref ref-type="aff" rid="I17">
<sup>17</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Buonomo</surname>
<given-names>Alessandro</given-names>
</name>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing—original draft</role>
<xref ref-type="aff" rid="I18">
<sup>18</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Bonamonte</surname>
<given-names>Domenico</given-names>
</name>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing—original draft</role>
<xref ref-type="aff" rid="I4">
<sup>4</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Napolitano</surname>
<given-names>Maddalena</given-names>
</name>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing—original draft</role>
<xref ref-type="aff" rid="I19">
<sup>19</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Bova</surname>
<given-names>Maria</given-names>
</name>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing—original draft</role>
<xref ref-type="aff" rid="I20">
<sup>20</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Pasquale</surname>
<given-names>Tiziana De</given-names>
</name>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing—original draft</role>
<xref ref-type="aff" rid="I21">
<sup>21</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Guarneri</surname>
<given-names>Fabrizio</given-names>
</name>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing—original draft</role>
<xref ref-type="aff" rid="I7">
<sup>7</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Patruno</surname>
<given-names>Cataldo</given-names>
</name>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing—original draft</role>
<xref ref-type="aff" rid="I8">
<sup>8</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hansel</surname>
<given-names>Katharina</given-names>
</name>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing—original draft</role>
<xref ref-type="aff" rid="I5">
<sup>5</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Filon</surname>
<given-names>Francesca Larese</given-names>
</name>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing—original draft</role>
<xref ref-type="aff" rid="I22">
<sup>22</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zaza</surname>
<given-names>Ippolita</given-names>
</name>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing—original draft</role>
<xref ref-type="aff" rid="I3">
<sup>3</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Testi</surname>
<given-names>Sergio</given-names>
</name>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing—original draft</role>
<xref ref-type="aff" rid="I23">
<sup>23</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Gangemi</surname>
<given-names>Sebastiano</given-names>
</name>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing—original draft</role>
<xref ref-type="aff" rid="I24">
<sup>24</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Foti</surname>
<given-names>Caterina</given-names>
</name>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing—original draft</role>
<xref ref-type="aff" rid="I4">
<sup>4</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Stingeni</surname>
<given-names>Luca</given-names>
</name>
<xref ref-type="aff" rid="I5">
<sup>5</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Nettis</surname>
<given-names>Eustachio</given-names>
</name>
<role content-type="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing—original draft</role>
<xref ref-type="aff" rid="I3">
<sup>3</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Corazza</surname>
<given-names>Monica</given-names>
</name>
<role content-type="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing—original draft</role>
<xref ref-type="aff" rid="I6">
<sup>6</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Rossi</surname>
<given-names>Oliviero</given-names>
</name>
<role content-type="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing—original draft</role>
<xref ref-type="aff" rid="I25">
<sup>25</sup>
</xref>
</contrib>
<contrib contrib-type="editor">
<name>
<surname>Sahiner</surname>
<given-names>Umit Murat</given-names>
</name>
<role>Academic Editor</role>
<aff>Hacettepe University Faculty of Medicine, Turkey</aff>
</contrib>
</contrib-group>
<aff id="I1">
<sup>1</sup>Department of Experimental and Clinical Medicine, University of Florence, 50134 Florence, Italy</aff>
<aff id="I2">
<sup>2</sup>Allergology and Clinical Immunology Unit, San Donato Hospital, 52100 Arezzo, Italy</aff>
<aff id="I3">
<sup>3</sup>Department of Emergency and Organ Transplantation, School and Chair of Allergology and Clinical Immunology, University of Bari - Aldo Moro, 70100 Bari, Italy</aff>
<aff id="I4">
<sup>4</sup>Section of Dermatology and Venereology, Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J), University of Bari - Aldo Moro, 70124 Bari, Italy</aff>
<aff id="I5">
<sup>5</sup>Dermatology Section, Department of Medicine and Surgery, University of Perugia, 06100 Perugia, Italy</aff>
<aff id="I6">
<sup>6</sup>Section of Dermatology and Infectious Diseases, Department of Medical Sciences, University of Ferrara, 44121 Ferrara, Italy</aff>
<aff id="I7">
<sup>7</sup>Department of Clinical and Experimental Medicine, Section of Dermatology, University of Messina, 98121 Messina, Italy</aff>
<aff id="I8">
<sup>8</sup>Department of Health Sciences, Magna Graecia University of Catanzaro, 88100 Catanzaro, Italy</aff>
<aff id="I9">
<sup>9</sup>Department of Medical Sciences and Public Health, and Unit of Internal Medicine, University of Cagliari, Policlinico Universitario - AOU di Cagliari Azienda Ospedaliero Universitaria, 09042 Monserrato, Italy</aff>
<aff id="I10">
<sup>10</sup>Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, 80131 Napoli, Italy</aff>
<aff id="I11">
<sup>11</sup>Unit of Dermatology, Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy</aff>
<aff id="I12">
<sup>12</sup>Studio Medico Cugia15, 09100 Cagliari, Italy</aff>
<aff id="I13">
<sup>13</sup>Department of Translational Medical Sciences, Allergy and Clinical Immunology, Center for Basic and Clinical Immunology Research (CISI), WAO Center of Excellence, University of Naples Federico II, 80131 Naples, Italy</aff>
<aff id="I14">
<sup>14</sup>Section of Dermatology, Department of Health Sciences, University of Genoa, IRCCS Ospedale Policlinico San Martino, 16100 Genoa, Italy</aff>
<aff id="I15">
<sup>15</sup>Department of Laboratory Medicine, ASFO, Pordenone Hospital, 33170 Pordenone, Italy</aff>
<aff id="I16">
<sup>16</sup>Internal Medicine Unit, Ospedale dell’Angelo, 30100 Venice, Italy</aff>
<aff id="I17">
<sup>17</sup>Laboratorio Unico Metropolitano, Maggiore Hospital AUSL Bologna, 40133 Bologna, Italy</aff>
<aff id="I18">
<sup>18</sup>Allergy Unit, Fondazione Policlinico Gemelli IRCCS, 00042 Rome, Italy</aff>
<aff id="I19">
<sup>19</sup>Dipartimento di Medicina e Scienze della Salute “Vincenzo Tiberio”, Rheumatology Unit, University of Molise, 86100 Campobasso, Italy</aff>
<aff id="I20">
<sup>20</sup>Department of Internal Medicine, Antonio Cardarelli Hospital, 80131 Naples, Italy</aff>
<aff id="I21">
<sup>21</sup>Division of Allergy, Civitanova Marche Hospital, 62012 Civitanova Marche, Italy</aff>
<aff id="I22">
<sup>22</sup>Clinical Unit of Occupational Medicine, University of Trieste, 34100 Trieste, Italy</aff>
<aff id="I23">
<sup>23</sup>Allergy and Clinical Immunology Unit, Azienda Sanitaria di Firenze, 50100 Florence, Italy</aff>
<aff id="I24">
<sup>24</sup>School and Operative Unit of Allergy and Clinical Immunology, Department of Clinical and Experimental Medicine, University of Messina, 98125 Messina, Italy</aff>
<aff id="I25">
<sup>25</sup>Immunoallergology Unit, Careggi University Hospital, 50100 Florence, Italy</aff>
<author-notes>
<fn id="afn1" fn-type="equal">
<label>†</label>
<p>These authors contributed equally to this work.</p>
</fn>
<corresp id="cor1">
<sup>*</sup>
<bold>Correspondence:</bold> Margherita Perlato, Department of Experimental and Clinical Medicine, University of Florence, Largo Brambilla 3, 50134 Florence, Italy. <email>margherita.perlato@gmail.com</email></corresp>
</author-notes>
<pub-date pub-type="ppub">
<year>2024</year>
</pub-date>
<pub-date pub-type="epub">
<day>26</day>
<month>08</month>
<year>2024</year>
</pub-date>
<volume>2</volume>
<issue>5</issue>
<fpage>421</fpage>
<lpage>440</lpage>
<history>
<date date-type="received">
<day>16</day>
<month>05</month>
<year>2023</year>
</date>
<date date-type="accepted">
<day>13</day>
<month>05</month>
<year>2024</year>
</date>
</history>
<permissions>
<copyright-statement>© The Author(s) 2024.</copyright-statement>
<license xlink:href="https://creativecommons.org/licenses/by/4.0/">
<license-p>This is an Open Access article licensed under a Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, sharing, adaptation, distribution and reproduction in any medium or format, for any purpose, even commercially, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.</license-p>
</license>
</permissions>
<abstract>
<p id="absp-1">Allergic and immunologic skin diseases are becoming increasingly common and this requires clinicians to be able to recognize and diagnose them. A joint meeting (GET TOGETHER 2022) of the Italian Society of Allergy, Asthma and Clinical Immunology (SIAAIC) and the Italian Society of Allergological, Occupational and Environmental Dermatology (SIDAPA) aimed to review the current knowledge on the differential diagnosis of contact dermatitis, atopic dermatitis, hereditary angioedema, urticaria, and cutaneous mastocytosis. The most important aspects to take into consideration when faced with a new cutaneous manifestation are the clinical features of the lesions, their distribution, age of onset, and comorbidities/aggravating factors. The document does not aim to provide an exhaustive and comprehensive description of all allergic and immunologic skin diseases. Instead, it should be a reference tool for the clinician who is faced with the onset of a new skin manifestation and its differential diagnosis.</p>
</abstract>
<kwd-group>
<kwd>Differential diagnosis</kwd>
<kwd>skin</kwd>
<kwd>contact dermatitis</kwd>
<kwd>atopic dermatitis</kwd>
<kwd>hereditary angioedema</kwd>
<kwd>urticaria</kwd>
<kwd>cutaneous mastocytosis</kwd>
<kwd>allergy</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="s1">
<title>Introduction</title>
<p id="p-1">“People wear their health on their skin”, said Lauren Gravitz [<xref ref-type="bibr" rid="B1">1</xref>], and we have the responsibility to understand what it is telling us. To guide us through this process, the Italian Society of Allergy, Asthma and Clinical Immunology (SIAAIC) and Italian Society of Allergological, Occupational and Environmental Dermatology (SIDAPA) organized the GET TOGETHER 2022 initiative. It consisted of virtual meetings held by specialists in allergic and immunologic skin diseases in Italy between September and December 2022. Its primary aim was to discuss and review the current knowledge on the differential diagnosis of contact dermatitis (CD), atopic dermatitis (AD), hereditary angioedema (HAE), urticaria, and cutaneous mastocytosis (CM). This document aims at providing a reference tool for the clinician who is faced with the onset of a new skin manifestation, considering the increasing prevalence of allergic and immunologic skin disorders.</p>
</sec>
<sec id="s2">
<title>Contact dermatitis</title>
<p id="p-2">CD is an inflammatory skin disorder that includes irritant CD (ICD) and allergic CD (ACD) [<xref ref-type="bibr" rid="B2">2</xref>, <xref ref-type="bibr" rid="B3">3</xref>]. Up to 80% of CD is irritant and is commonly related to occupation, especially wet work. ICD is a nonimmunologic inflammation of the skin caused by contact with chemical, physical, or biological agents. Clinically, it presents as an acute monomorphic reaction that includes scaling, low-grade erythema, vesicles, or erosions; when it affects the hands, it is usually localized on the dorsum and fingers. It can resolve or progress to chronic ICD [<xref ref-type="bibr" rid="B2">2</xref>]. ACD is a cutaneous inflammatory delayed reaction caused by contact with a specific exogenous allergen, occupational and non-occupational, to which a person has developed allergic sensitization [<xref ref-type="bibr" rid="B3">3</xref>]. It commonly manifests as eczematous dermatitis, even if non eczematous clinical forms are also described (lichenoid, bullous, lymphomatoid). The acute phase is characterized by pruritus, erythema, edema, and vesicles usually confined to the area of direct exposure. Recurrent contact with the allergen causes chronic disease, characterized by lichenified erythematous plaques with variable hyperkeratosis and fissuring that may spread beyond the areas of direct exposure. Itching and swelling are key elements of the history. The hands, feet, and face (including the eyelids) are some of the common sites for ACD (<xref ref-type="fig" rid="fig1">Figure 1</xref>) [<xref ref-type="bibr" rid="B3">3</xref>]. Diagnosis is mainly clinical, while histological features are not specific. ICD and ACD can be clinically indistinguishable; however, in ICD, burning exceeds itching and it does not spread beyond the area of contact after continued exposure [<xref ref-type="bibr" rid="B2">2</xref>]. Patch testing is fundamental for the identification of causal allergens in ACD [<xref ref-type="bibr" rid="B3">3</xref>] and to exclude ACD in cases with suspected chronic irritant dermatitis [<xref ref-type="bibr" rid="B2">2</xref>]. Metals, especially nickel sulfate, fragrance mix, isothiazolinones, and para-phenylenediamine are the most commonly positive allergens. Herein we will focus on the most common differentials of CD: AD, dermatophytosis, seborrheic dermatitis (SD), psoriasis (PSO), and dyshidrosis.</p>
<fig id="fig1" position="float">
<label>Figure 1</label>
<caption>
<p id="fig1-p-1">Contact dermatitis. (A) Allergic cheilitis from Peru balsam-containing lipstick; (B) allergic contact dermatitis (ACD) due to nickel sulfate; (C) ACD due to fragrance mix and Peru balsam; (D) ACD to cobalt-dichloride after wearing a tank top; (E) irritant contact dermatitis (ICD) in houseworker; (F) ACD to chrome thiuram mix in bricklayer. Used with permission from Dr. Stefano Francalanci, Allergological and Occupational Dermatology Unit, Department of Surgery and Translational Medicine, University of Florence</p>
</caption>
<graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="eaa-02-100955-g001.tif" />
</fig>
<sec id="t2-1">
<title>CD vs. AD</title>
<p id="p-3">Differential diagnosis between atopic and contact eczema is based on several clinical characteristics. While AD affects patients with a personal and family history of atopy, patients who suffer from ICD or ACD generally lack a story of atopy and hardly ever experienced allergic diseases, such as rhinitis, conjunctivitis, or asthma. Age of onset is also important since AD usually starts in childhood while CD typically occurs in adulthood, often as an occupational disease. Another factor to consider is the localization of the lesions. CD distribution depends on the site of exposure and it often provides valuable information about the sensitizing agent. For example, ACD can manifest at the earlobe when patients wear nickel-containing earrings and occupational CD usually affects the hands, thus investigating “working gestures” can be important. Localization of AD changes overtime: in the adult patient, it shows on the face (eyelids and perioral region), neck, antecubital folds, and popliteal fossae. In AD, eczematous lesions can be accompanied by other signs such as Dennie-Morgan infraorbital fold, marked xerosis, pityriasis alba, cheilitis, keratosis pilaris, and palmar hyperlinearity [<xref ref-type="bibr" rid="B2">2</xref>, <xref ref-type="bibr" rid="B4">4</xref>–<xref ref-type="bibr" rid="B6">6</xref>]. As for hand eczema, while the dorsal aspect of hands, digits, and interdigital spaces can be involved both in CD and AD, palmar involvement suggests a CD (cumulative use of detergents, repeated microtrauma). While CD resolves after removal of the noxa, AD has a chronic relapsing course that can show seasonal changes (generally worsening in winter and improving in summer) and worsen with physical stimuli such as sweating, wool fabrics, or soaps. Though there are no laboratory tests specific for these conditions, AD can be associated with high levels of IgE. Furthermore, prolonged and frequent exposure to potential allergens found in personal care and topical products used to treat chronic AD may predispose AD patients to developing ACD [<xref ref-type="bibr" rid="B7">7</xref>, <xref ref-type="bibr" rid="B8">8</xref>]. This should be suspected in the presence of lesions with atypical morphology despite appropriate treatment, immediate rebound after discontinuation, and failure to improve or worsen after initiation of topical therapy [<xref ref-type="bibr" rid="B9">9</xref>].</p>
</sec>
<sec id="t2-2">
<title>CD vs. dermatophytosis</title>
<p id="p-4">Tinea is a common superficial skin infection caused by dermatophytes belonging to three genera: <italic>Microsporum</italic>, <italic>Trichophyton</italic>, and <italic>Epidermophyton</italic>. Tinea may acquire various clinical aspects depending on inflammatory host response and damage to keratin. Tinea corporis is caused by the parasitization of dermatophytes on exposed glabrous skin. It is characterized by well-demarcated and sharply marginated patches with an erythematous and scaly surface. A raised border with vesicles, papules, or pustules is a distinguishing feature. The patches present a centrifugal spreading with central clearing that brings to an annular shape; coalescence of multiple lesions may result in bizarre configurations [<xref ref-type="bibr" rid="B10">10</xref>]. Hand involvement, tinea manuum (TM), is usually unilateral. It can be “dry”, with mild erythema and desquamation predominantly localized to palmar furrow, or “inflammatory” with vesicles and pustules that may mimic dyshidrotic eczema. It can be associated with foot involvement: tinea pedis. It usually involves the space between the fourth and fifth toes causing dryness, scaling, and fissures or wet and macerated aspects. Other possible forms are the dyshidrotic type, with erythema and vesicles that may leave a fine collarette after the rapture, and the moccasin type, with erythema, scaling, and occasionally hyperkeratotic lesions that may reach the lateral border of the foot where the typically raised edge of dermatophytosis can be observed [<xref ref-type="bibr" rid="B11">11</xref>]. In these cases, dermoscopic findings of scaling mainly located in the furrows can help us distinguish TM from hand eczema [<xref ref-type="bibr" rid="B12">12</xref>]. Most frequently, tinea can present as “two-foot, one hand syndrome”, mimicking CD. However, patch tests are negative, while direct microscopic examination of cutaneous scrapings may confirm the suspicion of fungal disorder. A definitive identification of the responsible agent requires culture in appropriate medium [<xref ref-type="bibr" rid="B11">11</xref>].</p>
</sec>
<sec id="t2-3">
<title>CD vs. PSO</title>
<p id="p-5">PSO is a common skin disorder characterized by erythematous plaques with characteristic adherent silvery-white scales. Lesions are typically localized at the knees, elbows, and scalp but other areas can be involved. Friction can cause the onset of psoriatic plaque (Koebner phenomenon). Its etiology is unclear: on a recognized genetic background, immune dysregulation, mainly Th1/Th17-driven, causes cytokine release with subsequent inflammation and keratinocyte proliferation [<xref ref-type="bibr" rid="B13">13</xref>–<xref ref-type="bibr" rid="B15">15</xref>]. <xref ref-type="table" rid="t1">Table 1</xref> summarizes the similarities and differences between PSO and CD. While in most cases, differences are quite defined, PSO with palmoplantar localization can be hard to distinguish from CD due to overlapping characteristics [<xref ref-type="bibr" rid="B16">16</xref>]. Furthermore, palmoplantar PSO predisposes to contact sensitization [<xref ref-type="bibr" rid="B17">17</xref>, <xref ref-type="bibr" rid="B18">18</xref>], thus patch testing should be performed to identify a possible sensitization that could benefit from preventive measures [<xref ref-type="bibr" rid="B19">19</xref>–<xref ref-type="bibr" rid="B21">21</xref>].</p>
<table-wrap id="t1">
<label>Table 1</label>
<caption>
<p id="t1-p-1">Characteristics of psoriasis and contact dermatitis for differential diagnosis</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th>
<bold>Characteristics</bold>
</th>
<th>
<bold>Psoriasis</bold>
</th>
<th>
<bold>Contact dermatitis</bold>
</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sites involved</td>
<td>Knees, elbows, scalps, palm and sole, all body</td>
<td>Sites in contact with irritants or allergens</td>
</tr>
<tr>
<td>Symptoms</td>
<td>Generally none</td>
<td>Burning in irritant form, itching in allergic form</td>
</tr>
<tr>
<td>Signs</td>
<td>Solitary or multiple erythematous plaques with characteristic adherent silvery white scales, Koebner phenomenon</td>
<td>Erythema, edema, papule and vesicles, fissures in irritant form; hyperkeratosis in chronic form</td>
</tr>
<tr>
<td colspan="3">Histology</td>
</tr>
<tr>
<td>    Parakeratosis</td>
<td>Moderate or strong, confluent; para-/ortho-keratosis</td>
<td>Mild and in multiple foci</td>
</tr>
<tr>
<td>    Acanthosis</td>
<td>Regular</td>
<td>More irregular</td>
</tr>
<tr>
<td>    Granular layer</td>
<td>Thinner</td>
<td>Normal</td>
</tr>
<tr>
<td>    Capillaries in the upper dermis</td>
<td>Tortuous or dilatate</td>
<td>Horizontal</td>
</tr>
<tr>
<td>    Lymphocytic exocytosis in epidermis</td>
<td>No (less likely)</td>
<td>Yes</td>
</tr>
<tr>
<td>    Edema of papillary dermis</td>
<td>No (less likely)</td>
<td>Yes</td>
</tr>
<tr>
<td>    Spongiosis</td>
<td>More frequent</td>
<td>Less frequent</td>
</tr>
<tr>
<td>    Munro microabscesses</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>Prevention</td>
<td>Not available</td>
<td>Avoidance of contact with irritants or sensitizing agents</td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
<sec id="t2-4">
<title>CD vs. SD</title>
<p id="p-6">SD is a common chronic dermatosis characterized by erythematous and desquamative lesions localized in those areas in which sebaceous glands are highly active (head, face, chest, and skin folds). It can affect infants and adults (M &gt; F), as well as special patient groups such as immunocompromised (AIDS, organ transplant recipients) and neuropsychiatric disease (Parkinson’s and neuroleptic-induced parkinsonism, drug and alcohol addiction and subsequent malnourishment) [<xref ref-type="bibr" rid="B22">22</xref>]. Different factors can contribute to its development, most importantly seborrhea (an altered composition of cutaneous lipidic biofilm resulting in an oily-looking skin) and overgrowth of the yeast <italic>Malassezia</italic> spp., which may lead to inflammation [<xref ref-type="bibr" rid="B23">23</xref>]. Infantile SD is localized at skin folds, where lesions may be oozing and lack scale, the scalp, and the forehead [<xref ref-type="bibr" rid="B24">24</xref>]. The involvement of the diaper area is frequent (up to 10% of the newborn) during the first 6 to 9 months of life [<xref ref-type="bibr" rid="B25">25</xref>] and needs to be differentiated from CD. In fact, ICD is often caused by feces with worsening factors such as chemical irritants, increased pH, and excessively hydrated skin [<xref ref-type="bibr" rid="B24">24</xref>]. ACD can also occasionally cause diaper dermatitis, due to fragrances, preservatives, and emulsifiers, although much less common than ICD or SD [<xref ref-type="bibr" rid="B24">24</xref>]. In adulthood, SD is characterized by sharply demarcated, yellow to brown, greasy scaling patches and plaques affecting the scalp, ears, face, pre-sternal chest, and more rarely intertriginous areas. SD and CD usually differ not only in the typical distribution of the lesions but also in the type of desquamation, which is greasy in SD.</p>
</sec>
<sec id="t2-5">
<title>CD vs. dyshidrosis</title>
<p id="p-7">Dyshidrosis is a common chronic dermatitis of the hands and feet that may cause occupational impairment and significant physical and psychological distress [<xref ref-type="bibr" rid="B26">26</xref>]. Both the pathogenesis and the prevalence of dyshidrosis are not known, but it is more common in young adults and affects men and women equally. It appears suddenly, mainly during warm seasons [<xref ref-type="bibr" rid="B27">27</xref>, <xref ref-type="bibr" rid="B28">28</xref>], and is very pruriginous. Clinically, it manifests as a recurrent vesicular—not erythematous—eruption affecting the hands and feet, particularly the lateral and dorsal aspects of the digits [<xref ref-type="bibr" rid="B27">27</xref>]. The lesions persist for several weeks and resolve with desquamation [<xref ref-type="bibr" rid="B29">29</xref>]. On the contrary, ACD manifests with different clinical phases. In the acute phase, it may present with a localized, well-demarcated skin eruption most commonly on the hands or face, but it can also be more widespread [<xref ref-type="bibr" rid="B30">30</xref>]. Chronic ACD usually shows lichenification, fissuring, and scale [<xref ref-type="bibr" rid="B30">30</xref>]. Dyshidrosis is usually a chronic condition and recurrence is possible, while ACD relapses on contact with the culprit allergen. Besides the clinical characteristics of the lesions, differential diagnoses can be guided by a combination of history and patch test results.</p>
</sec>
</sec>
<sec id="s3">
<title>Atopic dermatitis</title>
<p id="p-8">AD is a chronic and recurrent inflammatory skin disease caused by a complex interplay between the immune system, characterized by type 2 inflammation, the environment, and genetics, with mutations in genes encoding for structural proteins such as filaggrin (FLG), claudin 1 (CLDN1), and others [<xref ref-type="bibr" rid="B31">31</xref>]. The clinical characteristics of the lesions change over time and according to the age of onset. In infancy, we can find poorly defined erythematous patches or infiltrating erythematous-edematous plaques with papule microvesiculations and serous erosions, exacerbated by scratching, that progress from a wet to a crusty phase. These localize on the face, but the periorbital and perioral regions are normally uninvolved. In later childhood and adolescence, lesions primarily develop on the wrists, neck, antecubital, and popliteal fossae; eczematous cheilitis and eyelid dermatitis can also manifest. Acute flexural surface lesions present with painful fissures, erythematous patches or plaques, together with moist or crusty linear or punctiform erosions. On the other hand, lichenification, a thickening of the skin with accentuation of the pattern, is the main feature in the chronic stages. In eyelid dermatitis, signs of persistence are subpalpebral Dennie-Morgan folds and alopecia of the outer third of the eyebrows (Hertoghe sign). In adulthood, the lesions closely resemble that of an adolescent, but localization may narrow to the hands and eyelids (<xref ref-type="fig" rid="fig2">Figure 2</xref>). In the darker phototypes, AD might present as follicular eczema, which causes itchy follicular papules in the acute phase, and follicular lichenification, with punctiform desquamation in the chronic phase. Prurigo nodularis is common in older or extensively sensitized individuals, while others may show white dermographism and pityriasis alba [<xref ref-type="bibr" rid="B32">32</xref>]. An adult with newly developed dermatitis who has no history of childhood eczema or atopic disease should be evaluated for a variety of disorders. As a compass to guide us in the differential diagnosis of AD, we suggest evaluating the following items: time of onset, presence of itching, distribution of lesions, and skin features.</p>
<fig id="fig2" position="float">
<label>Figure 2</label>
<caption>
<p id="fig2-p-1">Atopic dermatitis (AD) manifestations stratified by age. (A) AD of the child; (B) eyelid dermatitis of the adult; (C) perioral cheilitis and Dennie-Morgan sign; (D) eczema of the hands</p>
</caption>
<graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="eaa-02-100955-g002.tif" />
</fig>
<sec id="t3-1">
<title>AD vs. SD</title>
<p id="p-9">As previously seen, clinical manifestations of SD vary between infants and adults. In infancy, SD appears within the first months of life, affecting the frontal and parietal hairy scalp with an oily-looking, thick and fissured crust (cradle cap); intertriginous folds of the neck, axillae, groin, and anogenital area can also be involved with clearly outlined erythematous patches. The absence of pruritus, early onset, greasy instead of dry scaling of skin, salmon red skin, and the presence of cradle cap should lead us to the diagnosis of SD. On the other hand, moderate to severe pruritus, forearms and shins involvement, and a history of allergy, particularly to food allergens (milk, egg, and other geographically relevant allergens), should guide us towards AD. In adulthood, differential diagnosis is easier and should be based on localization and clinical features. In SD, lesions involve the scalp, the retroauricular area, the face with a T-shape distribution (eyebrows, glabella nose, and nasolabial folds), and the trunk with V-shaped areas; hands, arms, and legs, typical areas of AD, are rarely affected in SD. Xerosis, lichenification, and scratch wounds are typical in AD. White dandruff of the scalp, follicular and perifollicular redness, and flaky scales with mild redness that evolves to petaloid lesions characterized by oily thick scales and crusts on a mild to severe erythema, are characteristic of SD [<xref ref-type="bibr" rid="B33">33</xref>].</p>
</sec>
<sec id="t3-2">
<title>AD vs. PSO</title>
<p id="p-10">PSO can manifest in different forms. An acute form, such as guttate PSO, that presents as distinct salmon-pink drop-shaped papules; silvery scales, unusually loosely adhered to the skin surface, can reveal a pinpoint bleeding when removed (Auspitz sign). This form can be easily distinguished from AD, because of the characteristics of the lesions and their distribution. On the other hand, chronic forms manifest with erythematous purplish plaques with sharp margins, that tend to form polycyclic lesions, covered by silvery-white scales tenaciously adhered to the underlying skin (oyster-shell-like lesions) [<xref ref-type="bibr" rid="B34">34</xref>]. In these cases, differential diagnosis can be more difficult. It is important to note that these lesions are typically symmetric and localized at the scalp and extensor aspects of the extremities, especially knees and elbows, while in AD, other areas are involved. Furthermore, itching can be considered a prodromal symptom in AD, while patients with PSO manifest itching only after the development of skin plaques. Nail findings can also be a useful tool when PSO is suspected. Inflammation of the nail matrix can cause pitting depressions, leukonychia, red spots in lunula, and nail plate crumbling. Nail bed involvement can result in onycholysis, oil-drop discoloration, nail bed hyperkeratosis, and splinter hemorrhages [<xref ref-type="bibr" rid="B35">35</xref>]. As seen earlier, AD typically manifests in young children with other manifestations or a familiar history of atopy, while PSO is not associated with atopy and the mean age of onset is 20 years.</p>
</sec>
<sec id="t3-3">
<title>AD vs. scabies</title>
<p id="p-11">Scabies (SC), the most common human ectoparasitosis, is caused by <italic>Sarcoptes scabiei</italic>. The pathognomonic lesions, burrows, are small serpiginous tunnels in the stratum corneum created by a mature female mite laying eggs and stools. In immunocompetent hosts, SC presents with pruritus exacerbating at night, which might be accompanied by crusted papules on erythematous patches. Burrows develop where the skin lacks adnexa and the epithelium is thin and soft, such as interdigital spaces, ulnar side of the hands, wrists, ankles, axillae, areolae (for women), waist, and groin [<xref ref-type="bibr" rid="B24">24</xref>, <xref ref-type="bibr" rid="B36">36</xref>]. In inveterate SC, reddish/purplish papules or nodules, with burrows on top, might develop, typically on the genital and scrotal area in men and breasts in women. Both SC and AD cause an intense generalized itching that leads to sleep disturbance; in the first case, it manifests with nocturnal exacerbations, awakening patients, while AD patients often complain of difficulty in falling asleep. The presence of contact cases within the family and the different distribution of lesions should also aid differential diagnosis. In immunocompromised patients, Norwegian SC can develop. It presents with thick, hyperkeratotic, grayish plaques with characteristic sand-like scales that cover vivid erythema; itching is not always present and the head and neck may be involved [<xref ref-type="bibr" rid="B24">24</xref>, <xref ref-type="bibr" rid="B36">36</xref>]. Norwegian SC is frequently misdiagnosed as eczema, SD, drug eruptions, Sezary syndrome, and PSO. Clinical confirmation of SC can only be made by detecting burrows with dermoscopy. Parasitological confirmation with a microscope is essential in cases of crusted SC or SC in healthcare settings, but failure to find mites is common and does not rule it out [<xref ref-type="bibr" rid="B24">24</xref>, <xref ref-type="bibr" rid="B36">36</xref>].</p>
</sec>
<sec id="t3-4">
<title>AD vs. mycosis fungoides</title>
<p id="p-12">AD and cutaneous T-cell lymphoma, particularly mycosis fungoides (MF), unlike B-cell lymphomas, share many analogies [<xref ref-type="bibr" rid="B37">37</xref>]. In childhood, the most frequent cutaneous lymphoma is MF, especially the pilotropic and the hypopigmented patterns, which should be distinguished from pityriasis alba [<xref ref-type="bibr" rid="B38">38</xref>, <xref ref-type="bibr" rid="B39">39</xref>]. In patients with adult-onset AD, differential diagnosis with MF, especially in the early stages, might be difficult [<xref ref-type="bibr" rid="B40">40</xref>] because MF can manifest as variably erythematous, finely scaling lesions, hypopigmented or hyperpigmented patches [<xref ref-type="bibr" rid="B39">39</xref>, <xref ref-type="bibr" rid="B41">41</xref>–<xref ref-type="bibr" rid="B45">45</xref>]. Skin lesions can become confluent, develop into erythroderma, or occur directly as erythroderma [<xref ref-type="bibr" rid="B41">41</xref>, <xref ref-type="bibr" rid="B46">46</xref>, <xref ref-type="bibr" rid="B47">47</xref>]. Partial loss of elastic fibers and atrophy of the epidermis (characteristic of a long-standing lesion) may confer a typical wrinkled appearance “cigarette paper-like” and represent a clue against an inflammatory dermatosis [<xref ref-type="bibr" rid="B39">39</xref>]. The fixed character of the lesions, their annular or figurate appearance due to partial spontaneous regression, and the localization of the lesions on photo-protected sites may help to distinguish MF from AD [<xref ref-type="bibr" rid="B46">46</xref>]. A histopathological examination is essential for diagnosis since epidermotropism of atypical lymphocytes is a distinguishing feature of MF and is not seen in AD [<xref ref-type="bibr" rid="B46">46</xref>]. However, in the early stages of MF, epidermotropism is not always evident, thus immunohistochemistry and research for T cell receptor (TCR) monoclonal rearrangement are essential.</p>
</sec>
<sec id="t3-5">
<title>AD vs. dermatomyositis</title>
<p id="p-13">Dermatomyositis (DM) belongs to the idiopathic inflammatory myopathies (IIMs), a diverse group of diseases that affect the skeletal muscles and frequently coexist with extramuscular involvements including, cancer, interstitial lung disease (ILD), and rheumatoid arthritis [<xref ref-type="bibr" rid="B48">48</xref>]. Up to 20% of patients with recognized DM skin features do not or only partially manifest muscle dysfunction. “Clinically amyopathic” DM (CADM) may be difficult to diagnose [<xref ref-type="bibr" rid="B49">49</xref>]. Skin findings include Gottron’s papules (violaceous erythematous papules over interphalangeal joints) and Gottron’s sign (symmetric macular violaceous erythema over interphalangeal joints, olecranon processes, patellas, medial malleoli), both of which have been proposed to be “pathognomonic”. “Characteristic” skin findings include heliotrope rash (periorbital violaceous erythema), periungual telangiectasias and dystrophic cuticles, macular violaceous erythema over dorsal hands, forearms, arms, shoulders (shawl sign), V area of neck and chest, and lateral surface of the thighs or hips (Holster sign). “Compatible” findings include poikiloderma atrophicans vascularis, subepidermal bullous lesions and superficial erosions, and calcinosis cutis [<xref ref-type="bibr" rid="B48">48</xref>]. Besides the identification of pathognomonic and characteristic lesions, DM can also be differentiated from AD with the aid of autoantibodies. Furthermore, DM can manifest in association with ILD and cancer.</p>
</sec>
</sec>
<sec id="s4">
<title>Hereditary angioedema</title>
<p id="p-14">HAE is a rare genetic disease characterized by recurrent episodes of cutaneous or submucosal edema, due to an increase of bradykinin, that leads to temporary enhanced vascular permeability. First described by Osler in 1888 as “hereditary angioneurotic oedema”, different forms of this disease have now been identified and genetically characterized [<xref ref-type="bibr" rid="B50">50</xref>]. The most common ones are associated with a defect of the C1-inhibitor (C1-INH) production (HAE type I, ~85% of cases) or function (HAE type II, ~15% of cases). In fact, over 450 mutations in the <italic>SERPING1</italic> gene have been reported. More recently, mutations of other genes have been associated with HAE, they encode for proteins such as factor 12 (FXII), angiopoietin-1 (ANGPT1), plasminogen (PLG), kininogen 1 (KNG1), myoferlin (MYOF), or heparan sulfate-glucosamine 3-O-sulfotransferase 6 (HS3ST6) [<xref ref-type="bibr" rid="B51">51</xref>]. Attacks most frequently involve the upper respiratory tract, extremities, and abdomen, though genitals, muscles, joints, and bladder can also be affected (<xref ref-type="fig" rid="fig3">Figure 3</xref>). They have a self-limiting course, variable duration, and are characterized by intense pain and deformity of the involved sites [<xref ref-type="bibr" rid="B52">52</xref>]. Laryngeal attacks can be the first manifestation of disease and can occur in over 50% of patients; if left untreated, they can lead to death [<xref ref-type="bibr" rid="B53">53</xref>]. Swelling can be anticipated by prodromal symptoms and signs such as fatigue, tingling, and marginate erythema. Symptoms usually manifest early in childhood, worsen during puberty, and fluctuate during the patient’s lifetime. A positive family history can aid the diagnosis, though it may not be present in up to 25% of cases, and severity and localization may vary among the same genetic kindred [<xref ref-type="bibr" rid="B51">51</xref>]. Measurement of plasma C4 levels, C1-INH protein, and C1-INH function are required for the diagnosis of HAE type I and II. Currently, HAE with normal C1-INH can only be diagnosed by genetic testing as there are no laboratory tests available. The differential diagnoses of HAE should take into consideration bradykinin-mediated types of acquired AE, such as acquired AE due to C1-INH deficiency (AAE-C1-INH) and angiotensin converting enzyme inhibitor (ACE-I)-AE, and histaminergic AE [idiopathic histaminergic acquired AE (IH-AAE)] in patients with chronic spontaneous urticaria (CSU) without wheals or allergic AE, as well as idiopathic acquired AE and abdominal pain attacks [<xref ref-type="bibr" rid="B54">54</xref>].</p>
<fig id="fig3" position="float">
<label>Figure 3</label>
<caption>
<p id="fig3-p-1">Hereditary angioedema (HAE) of the face before treatment</p>
</caption>
<graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="eaa-02-100955-g003.tif" />
</fig>
<sec id="t4-1">
<title>HAE vs. abdominal pain</title>
<p id="p-15">Abdominal pain occurs in 43% to 93% of patients with HAE. Approximately one third of patients with abdominal attacks undergo unnecessary surgery, such as appendectomy and exploratory laparotomy [<xref ref-type="bibr" rid="B55">55</xref>]. Pain localization is variable since the whole intestine, stomach, and colon can be affected. It may manifest as severe acute abdominal pain, often described as cramping or colicky, or as chronic recurrent abdominal pain of varying severity [<xref ref-type="bibr" rid="B56">56</xref>]. To date, there is no reliable marker to define abdominal AE upon presentation of symptoms. Blood tests are not decisive because they can show an elevation of leucocytes, which is present in many other abdominal conditions [<xref ref-type="bibr" rid="B55">55</xref>]. However radiologic imaging performed with the correct timing is extremely important: ultrasound or CT scan allows to identify the transitional presence of abundant free fluid in the abdominal cavity and intestinal swelling, which spontaneously disappears [<xref ref-type="bibr" rid="B57">57</xref>]. In conclusion, even in patients with a confirmed diagnosis of HAE, the diagnosis of an abdominal attack depends upon clinical judgment and is supported by imaging findings and the efficacy of specific treatments [<xref ref-type="bibr" rid="B55">55</xref>].</p>
</sec>
<sec id="t4-2">
<title>HAE vs. AAE-C1-INH</title>
<p id="p-16">AAE-C1-INH is an extremely rare condition that can be caused by the presence of anti-C1-INH neutralizing antibodies and/or the consumption of C1-INH by neoplastic lymphoid cells. It is often associated with autoimmune diseases, lymphoproliferative diseases, or other malignancies; interestingly, AE attacks can precede several years of the onset of the hematological disease [<xref ref-type="bibr" rid="B58">58</xref>]. Symptoms of AAE-C1-INH are indistinguishable from those experienced by patients with HAE. Therefore, other clinical characteristics should be carefully taken into consideration when making the diagnosis. Besides the comorbidities associated with AAE-C1-INH, another distinguishing feature of the disease is its late age of onset, as it often manifests after the fourth decade of life. The lack of family history of recurrent AE attacks should also guide the diagnosis [<xref ref-type="bibr" rid="B59">59</xref>]. Laboratory test results show a reduction of the complement component C4, during and between attacks, and lower levels of the functional C1-INH test. This, however, is also seen in patients with HAE. A useful tool to aid the diagnosis is the measurement of the C1q level, as it is decreased only in AAE-C1-INH [<xref ref-type="bibr" rid="B54">54</xref>]. In conclusion, AAE-C1-INH should be suspected in all patients with a late onset of AE who have autoimmune or lymphoproliferative diseases; measurement of the C1q can help to discriminate between other forms of AE.</p>
</sec>
<sec id="t4-3">
<title>HAE vs. ACE-Is and other drug-induced AE</title>
<p id="p-17">Drug-induced AE can be divided into three categories. The first one comprises IgE-mediated hypersensitivity reactions, with the drugs most commonly involved being penicillins, cephalosporins, iodinated organ contrast agents, neuromuscular blocking agents, pyrazolones, quinolones, and non-steroidal anti-inflammatory drugs (NSAIDs). In the case of NSAIDs, however, the most frequently involved mechanism is the non-allergic inhibition of cyclooxygenase, which leads to alterations in the metabolism of arachidonic acid and the overproduction of cysteinyl leukotriene [<xref ref-type="bibr" rid="B60">60</xref>]. The third type of drug-induced AE is a bradykinin-mediated type of acquired AE [<xref ref-type="bibr" rid="B61">61</xref>]; the drugs most frequently involved are ACE-Is. ACE is involved in the degradation of bradykinin, which can accumulate, thus leading to vasodilation and increased vascular permeability through the production of nitric oxide and prostaglandins [<xref ref-type="bibr" rid="B62">62</xref>]. The incidence of AE in patients taking ACE-Is ranges from 1 to 7 events per 1,000 patients [<xref ref-type="bibr" rid="B63">63</xref>]. Individuals with an intrinsic defect in bradykinin degradation have a propensity to develop AE with ACE-I. Furthermore, ACE also acts by degrading substance P, a peptide with vasodilatory properties. Angiotensin receptor blockers (ARBs) have also been associated with the development of AE, though the mechanism is not fully understood. In some cases, the appearance of IgG and IgA autoantibodies against ARBs, with cross-reactivity towards complement 1-esterase inhibitor, has been observed [<xref ref-type="bibr" rid="B64">64</xref>]. Fundamental in the differential diagnosis is the anamnesis, especially aimed at identifying drugs frequently associated with AE. Clinically, the lips, tongue, face, and upper airway are most commonly affected, though the intestine can also be involved. In these patients, C1-INH levels and function are within the normal range.</p>
</sec>
<sec id="t4-4">
<title>HAE vs. IH-AAE</title>
<p id="p-18">IH-AAE is one of the most common causes of AE without urticaria [<xref ref-type="bibr" rid="B65">65</xref>]. The etiology of IH-AAE is unknown, but the interruption of recurrences after administration of H1-histamine receptor blockers suggests an important role of mast cells and/or blood basophils in its pathogenesis [<xref ref-type="bibr" rid="B66">66</xref>]. IH-AAE typically spreads in minutes or a few hours, reaching its maximum within six hours, and resolves within 12–24 h [<xref ref-type="bibr" rid="B66">66</xref>, <xref ref-type="bibr" rid="B67">67</xref>]. Nevertheless, Faisant et al. [<xref ref-type="bibr" rid="B68">68</xref>] reported a case series of 31 patients whose IH-AAE attacks lasted on average 28 h, suggesting that IH-AAE may last more than 24 h. IH-AAE involves the face and extremities, with a sparing of gastrointestinal mucosa [<xref ref-type="bibr" rid="B66">66</xref>, <xref ref-type="bibr" rid="B67">67</xref>]. Some authors describe no involvement of laryngeal mucosa [<xref ref-type="bibr" rid="B66">66</xref>], while others report swelling of the upper respiratory tract in more than half of cases [<xref ref-type="bibr" rid="B67">67</xref>]. Despite these clinical manifestations, response to antihistamines makes the prognosis good, with no intubation or death reported [<xref ref-type="bibr" rid="B66">66</xref>, <xref ref-type="bibr" rid="B68">68</xref>]. IH-AAE may present recurrences for months or years [<xref ref-type="bibr" rid="B67">67</xref>]. Diagnosis is based on prompt response to antihistamines and exclusion of other causes of AE, such as allergic triggers (drugs, foods, or other environmental allergens), infections, autoimmune diseases, and C1-INH deficiency. Differential diagnosis between IH-AAE and HAE is based on anamnestic, clinical, and laboratory features, as well as different responses to treatment. In IH-AAE patients, there is no family history of AE and the disease may present at any age, without predilection for childhood [<xref ref-type="bibr" rid="B66">66</xref>, <xref ref-type="bibr" rid="B69">69</xref>]. Symptoms of IH-AAE usually last less than those of HAE and are not accompanied by prodromal symptoms [<xref ref-type="bibr" rid="B52">52</xref>, <xref ref-type="bibr" rid="B67">67</xref>], and patients do not experience abdominal pain [<xref ref-type="bibr" rid="B66">66</xref>]. Plasma levels and activity of C1-INH are normal. Finally, antihistamines markedly improve IH-AAE but have no effect on hereditary forms of AE [<xref ref-type="bibr" rid="B52">52</xref>, <xref ref-type="bibr" rid="B69">69</xref>].</p>
</sec>
</sec>
<sec id="s5">
<title>Chronic spontaneous urticaria</title>
<p id="p-19">Urticaria is a disorder characterized by the development of transient wheals (&lt; 24 h), AE, or both (<xref ref-type="fig" rid="fig4">Figure 4</xref>) [<xref ref-type="bibr" rid="B70">70</xref>]. Urticaria is classified into different subtypes based on the duration of symptoms (i.e., acute ≤ 6 weeks or chronic &gt; 6 weeks) and the relevance of the eliciting factor (i.e., spontaneous if no specific eliciting factor is involved, or inducible if one is identified) [<xref ref-type="bibr" rid="B70">70</xref>]. CSU is a highly heterogeneous condition that may hide potential underlying causes such as autoimmunity and infections [<xref ref-type="bibr" rid="B71">71</xref>]. In addition, a wide variety of skin and systemic disorders may mimic CSU, making the differential diagnosis a challenge in the clinical practice. Herein we will focus on the most common differential diagnosis of CSU including urticarial dermatitis (UD), dermatitis herpetiformis (DH), urticarial vasculitis (UV), and bullous pemphigoid (BP).</p>
<fig id="fig4" position="float">
<label>Figure 4</label>
<caption>
<p id="fig4-p-1">Different urticaria phenotypes. (A) Chronic spontaneous urticaria (CSU) of the trunk; (B) serpiginous and confluent CSU lesions of the back; (C) small punctiform CSU lesions of the limbs; (D) CSU of the neck in a young woman</p>
</caption>
<graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="eaa-02-100955-g004.tif" />
</fig>
<sec id="t5-1">
<title>CSU vs. UD</title>
<p id="p-20">UD is defined as a clinical entity presenting with itchy, erythematous plaques, and papules resembling urticaria, individually lasting longer than 24 h sometimes accompanied by eczematous lesions [<xref ref-type="bibr" rid="B72">72</xref>, <xref ref-type="bibr" rid="B73">73</xref>]. The pathophysiology is thought to be a delayed type of hypersensitivity reaction [<xref ref-type="bibr" rid="B72">72</xref>, <xref ref-type="bibr" rid="B74">74</xref>]. Clinical presentation may include the concomitance of plaques of urticated erythema and eczematous dermatitis-like areas or isolated urticarial papules and/or urticated patches [<xref ref-type="bibr" rid="B72">72</xref>, <xref ref-type="bibr" rid="B74">74</xref>]. Clinical diagnosis may be challenging, especially when urticarial plaques rather than papules dominate the clinical presentation, as this condition may clinically mimic urticaria and other dermatological conditions such as UV, BP, DH, papular urticaria, drug reaction, viral exanthem, and herpes gestationis [<xref ref-type="bibr" rid="B72">72</xref>]. It is important to remember that the urticarial component of UD differs from conventional urticaria since the latter resolves in &lt; 24 h [<xref ref-type="bibr" rid="B75">75</xref>]. Furthermore, UD primarily affects older patients (mean age of approximately 60 years) [<xref ref-type="bibr" rid="B72">72</xref>, <xref ref-type="bibr" rid="B74">74</xref>], with a female predominance, and can sometimes be secondary to other underlying diseases [<xref ref-type="bibr" rid="B74">74</xref>]. A retrospective study showed that 15% of patients had a history of malignancies (e.g., myelodysplastic syndrome, pancreatic adenocarcinoma [<xref ref-type="bibr" rid="B76">76</xref>], prostate cancer, and vulval cancer) [<xref ref-type="bibr" rid="B74">74</xref>]. Association with autoimmune disorders and drug administration, such as rituximab and vaccines, has also been reported [<xref ref-type="bibr" rid="B77">77</xref>–<xref ref-type="bibr" rid="B79">79</xref>]. Cutaneous biopsies can be a useful diagnostic tool, usually revealing slight epidermal spongiosis with upper dermal perivascular lymphocytes and interstitial eosinophils with or without neutrophils and normal stratum corneum, in the absence of epidermal vesiculation or parakeratosis [<xref ref-type="bibr" rid="B72">72</xref>, <xref ref-type="bibr" rid="B80">80</xref>].</p>
</sec>
<sec id="t5-2">
<title>CSU vs. DH</title>
<p id="p-21">DH is a rare cutaneous disease that can be considered the extraintestinal manifestation of celiac disease [<xref ref-type="bibr" rid="B81">81</xref>]. As celiac disease, it is strictly associated with human leukocyte antigen (HLA) DQ2 and DQ8 haplotypes [<xref ref-type="bibr" rid="B82">82</xref>] and it is caused by an autoimmune response to epidermal transglutaminase (TG3/eTG). It can occur at any age but affects primarily people between 30 to 40 years of age. The lesions are typically symmetric and usually visible in the extensor areas: lower limbs, elbows, dorsal forearms, buttocks, and sacral region. Scalp and neck are often affected, while mucosa oral lesions are spared [<xref ref-type="bibr" rid="B83">83</xref>]. The eruption is polymorphic with erythematous papules, urticarial plaques, and vesicles with serous or hemorrhagic content. Pruritus with burning sensation is an important clinical feature and many patients present erosions and crusted papules as a result of scratching [<xref ref-type="bibr" rid="B84">84</xref>]. Gastrointestinal symptoms occur only in 20% of patients [<xref ref-type="bibr" rid="B85">85</xref>]. As celiac disease, DH is associated with autoimmune diseases, such as thyroid disease, pernicious anemia, and type I diabetes, and a higher risk of non-Hodgkin lymphoma. Differential diagnoses with CSU should be guided primarily by the localization and duration of the lesions. The gold standard for the diagnoses is direct immunofluorescence (DIF) on skin biopsies, as it shows pathognomonic IgA deposits in a granular pattern in the dermal papillae and/or dermoepidermal junction [<xref ref-type="bibr" rid="B86">86</xref>]. Anti-TG3 antibodies are considered the primary diagnostic serology and are preferred over anti-TG2 antibodies for their superior specificity [<xref ref-type="bibr" rid="B87">87</xref>, <xref ref-type="bibr" rid="B88">88</xref>].</p>
</sec>
<sec id="t5-3">
<title>CSU vs. BP</title>
<p id="p-22">BP is the most common subepidermal autoimmune blistering disease and mostly affects individuals aged &gt; 60 years [<xref ref-type="bibr" rid="B89">89</xref>]. It is characterized by tissue-bound and circulating autoantibodies directed against components of hemidesmosomes involved in the dermal-epidermal cohesion: BP antigen 180, BP antigen 230, or both. Risk factors for BP include old age, neurologic diseases, and systemic therapies such as antibiotics, beta-blockers, NSAIDs, diuretics, anti-tumor necrosis factor (TNF)-α, dipeptidyl peptidase 4 inhibitors (DPP-4i), and immune checkpoint inhibitors [<xref ref-type="bibr" rid="B90">90</xref>]. Typically, it presents with tense blisters filled with serous and hemorrhagic fluid on erythematous skin. These blisters can persist for a few days before rupturing, leaving eroded and crusted areas. Predilection sites include the lower abdomen, the anterior and inner thighs, and the flexor region of the forearms. Mucous membranes are affected only in 10–35% of patients, with prevalent involvement of the oral mucosa, where blisters or erosions are generally non-scarring [<xref ref-type="bibr" rid="B91">91</xref>]. Up to 20% of BP patients have a “non-bullous prodromal phase” that lasts for weeks or months and, more rarely, some do not develop blisters at all (“non-bullous cutaneous pemphigoid”) [<xref ref-type="bibr" rid="B92">92</xref>]. Clinically this subtype of BP is characterized by intense pruritus which is associated with polymorphic lesions that are often urticarial in appearance, though in some cases lesions may be lacking. Diagnosis can be made by performing DIF of a biopsy from perilesional skin [<xref ref-type="bibr" rid="B90">90</xref>, <xref ref-type="bibr" rid="B93">93</xref>] that reveals linear deposition of IgG and C3 along the dermo-epidermal junction. Serological tests that may confirm the diagnosis of BP include indirect immunofluorescence (IIF) on epithelial substrates (monkey esophagus; salt split skin) and ELISA [<xref ref-type="bibr" rid="B90">90</xref>].</p>
</sec>
<sec id="t5-4">
<title>CSU vs. UV</title>
<p id="p-23">UV is a leukocytoclastic small vessel vasculitis that frequently involves dermal capillaries and postcapillary venules [<xref ref-type="bibr" rid="B94">94</xref>]. It is a rare disease, mostly affecting middle-aged women. Different triggering factors have been identified, such as infections, medication reactions, autoimmune diseases, underlying malignancies, and others, though often the underlying cause remains unknown. All these factors can lead to complement activation and the generation of C3a and C5a, which act as anaphylatoxins, leading to mast cell degranulation. Based on complement levels, UV can be divided into normocomplementemic UV (NUV) and hypocomplementemic UV (HUV) [<xref ref-type="bibr" rid="B95">95</xref>]. Clinically, in UV urticarial plaques persist for more than 24 h leaving residual hyperpigmentation or ecchymoses, while in CSU wheals generally undergo spontaneous resolution in 2 h to 8 h (and always within 24 h). Furthermore, frank signs of vasculitis/purpura may be observed. While UV is generally associated with itchy or even painful lesions in up to one-third of patients, patients with CSU experience only itching. Response to antihistamines can also aid in the differential diagnoses, as patients with UV do not respond even after up-dosing [<xref ref-type="bibr" rid="B96">96</xref>]. Laboratory exams show low C1q levels and normal C1-INH levels, in association with anti-C1q antibodies in 55% of patients with HUV. Histologically, skin samples reveal dermal capillaries and postcapillary venules with leukocytoclastic vasculitis (fragmentation of leukocytes with nuclear debris), fibrinoid deposits, perivascular infiltrates composed of neutrophils, extravasation of red blood cells, and injury and swelling of the endothelial cells. DIF often reveals immunoglobulin and complement linear deposition in or around blood vessels of the upper dermis and/or at the dermal-epidermal junction [<xref ref-type="bibr" rid="B97">97</xref>].</p>
</sec>
</sec>
<sec id="s6">
<title>Mastocytosis</title>
<p id="p-24">The term “mastocytosis” refers to a group of distinct disorders characterized by a clonal expansion of mast cells and their subsequent accumulation in different tissues and organs. It has been considered part of the myeloproliferative disorders for many years, but in 2016 it has been classified as an independent entity [<xref ref-type="bibr" rid="B98">98</xref>]. We can distinguish two forms of mastocytosis, the CM, where the skin is the only organ involved, and the systemic mastocytosis (SM) where many other organs, such as the bone marrow and bones, may be affected at the same time [<xref ref-type="bibr" rid="B98">98</xref>, <xref ref-type="bibr" rid="B99">99</xref>].</p>
<sec id="t6-1">
<title>CM vs. SM</title>
<p id="p-25">Skin involvement can be considered the most characteristic feature of both CM and SM. Cutaneous lesions may be single (mastocytoma of the skin) or multiple macules or papules, often showing a pathognomonic positive Darier sign (lesion urtication after local scratching) [<xref ref-type="bibr" rid="B100">100</xref>]. Color may vary from yellowish to red and brown and commonly affected areas are the trunk and the extremities, especially in adults with diffuse forms [<xref ref-type="bibr" rid="B100">100</xref>]. Maculopapular lesions are common in both children and adults with mastocytosis. However, SM is an extremely rare entity during childhood, while if “urticaria pigmentosa-like” lesions (<xref ref-type="fig" rid="fig5">Figure 5</xref>) are present in adulthood, SM should always be investigated [<xref ref-type="bibr" rid="B101">101</xref>]. Furthermore, the persistence of these lesions in adulthood suggests a possible transition to SM. The differential diagnosis between CM and SM is based on the involvement of other organs other than the skin, in the latter. Clinically, this can be suspected in the presence of flushing, itching, urticaria, abdominal pain, diarrhea, osteoporosis, hematological disorders, and anaphylactic reactions to several triggers [<xref ref-type="bibr" rid="B99">99</xref>]. A definite diagnosis requires bone marrow or other organ biopsies, to identify the presence of mast cells in aggregates [<xref ref-type="bibr" rid="B98">98</xref>, <xref ref-type="bibr" rid="B99">99</xref>].</p>
<fig id="fig5" position="float">
<label>Figure 5</label>
<caption>
<p id="fig5-p-1">Cutaneous mastocytosis urticaria pigmentosa of the adult. Used with permission from Dr. Gabriella Perillo, Resident in Dermatology, Department of Health Sciences, Section of Dermatology, University of Florence</p>
</caption>
<graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="eaa-02-100955-g005.tif" />
</fig>
</sec>
<sec id="t6-2">
<title>SM vs. hereditary alpha-tryptasemia</title>
<p id="p-26">Hereditary alpha-tryptasemia (HαT) is an autosomal dominant genetic condition, caused by increased copy numbers of the α-tryptase encoding gene (<italic>TPSAB1</italic>) on chromosome 16p13.3, resulting in elevated basal serum tryptase (BST) levels and multisystem disorders [<xref ref-type="bibr" rid="B102">102</xref>]. The prevalence of this condition has been estimated as 4–6 % in the general population [<xref ref-type="bibr" rid="B103">103</xref>]. Affected patients may have high normal (&gt; 8 ng/mL) or clearly high (&gt; 20 ng/mL) BST [<xref ref-type="bibr" rid="B104">104</xref>]. Clinical manifestations of HαT may resemble symptoms described in clonal mast cell disorders, including flushing, pruritus, and urticaria. Other symptoms are autonomic dysfunction, functional gastrointestinal symptoms (irritable bowel syndrome, dysmotility, and chronic gastroesophageal reflux), anaphylaxis (food-mediated, insect stings, and idiopathic), pain (chronic arthralgia, headache, and body pain), neuropsychiatric manifestations, and musculoskeletal abnormalities (joint hypermobility and retained primary dentition) [<xref ref-type="bibr" rid="B105">105</xref>, <xref ref-type="bibr" rid="B106">106</xref>]. Such as for clonal mast cell disorders, these symptoms can be chronic or episodic, sometimes induced by specific triggers, such as exercise, vibration, stress, food, heat, or physical trauma [<xref ref-type="bibr" rid="B107">107</xref>]. In contrast to SM, “urticaria pigmentosa-like” lesions are never present in HαT. However, recent studies have revealed a significantly higher HαT prevalence in patients with SM (12–17%) [<xref ref-type="bibr" rid="B103">103</xref>, <xref ref-type="bibr" rid="B107">107</xref>, <xref ref-type="bibr" rid="B108">108</xref>]. Therefore, the presence of mast cell associated disorders does not rule out the diagnosis of HαT. Furthermore, the coexistence of both disorders associates with a higher risk of life-threatening anaphylactic episodes and more severe mediator-related symptoms [<xref ref-type="bibr" rid="B106">106</xref>, <xref ref-type="bibr" rid="B109">109</xref>]. Thus, <italic>TPSAB1</italic> genotyping could be a novel biomarker for the risk of developing severe anaphylaxis in patients with mastocytosis.</p>
</sec>
</sec>
<sec id="s7">
<title>Conclusions</title>
<p id="p-27">The increasing prevalence of allergic and immunologic skin diseases requires clinicians to feel confident in distinguishing these common pathologies. This document does not aim to provide an exhaustive and comprehensive description of all these skin diseases. Instead, it focuses on critical clinical aspects that should be taken into consideration when navigating through the differential diagnosis of CD, AD, HAE, urticaria, and CM.</p>
</sec>
</body>
<back>
<glossary>
<title>Abbreviations</title>
<def-list>
<def-item>
<term>AAE-C1-INH</term>
<def>
<p>acquired angioedema due to C1-inhibitor deficiency</p>
</def>
</def-item>
<def-item>
<term>ACD</term>
<def>
<p>allergic contact dermatitis</p>
</def>
</def-item>
<def-item>
<term>ACE</term>
<def>
<p>angiotensin converting enzyme</p>
</def>
</def-item>
<def-item>
<term>ACE-I</term>
<def>
<p>angiotensin converting enzyme inhibitor</p>
</def>
</def-item>
<def-item>
<term>AD</term>
<def>
<p>atopic dermatitis</p>
</def>
</def-item>
<def-item>
<term>AE</term>
<def>
<p>angioedema</p>
</def>
</def-item>
<def-item>
<term>BP</term>
<def>
<p>bullous pemphigoid</p>
</def>
</def-item>
<def-item>
<term>C1-INH</term>
<def>
<p>C1-inhibitor</p>
</def>
</def-item>
<def-item>
<term>CD</term>
<def>
<p>contact dermatitis</p>
</def>
</def-item>
<def-item>
<term>CM</term>
<def>
<p>cutaneous mastocytosis</p>
</def>
</def-item>
<def-item>
<term>CSU</term>
<def>
<p>chronic spontaneous urticaria</p>
</def>
</def-item>
<def-item>
<term>DH</term>
<def>
<p>dermatitis herpetiformis</p>
</def>
</def-item>
<def-item>
<term>DIF</term>
<def>
<p>direct immunofluorescence</p>
</def>
</def-item>
<def-item>
<term>DM</term>
<def>
<p>dermatomyositis</p>
</def>
</def-item>
<def-item>
<term>HAE</term>
<def>
<p>hereditary angioedema</p>
</def>
</def-item>
<def-item>
<term>HαT</term>
<def>
<p>hereditary alpha-tryptasemia</p>
</def>
</def-item>
<def-item>
<term>ICD</term>
<def>
<p>irritant contact dermatitis</p>
</def>
</def-item>
<def-item>
<term>IH-AAE</term>
<def>
<p>idiopathic histaminergic acquired angioedema</p>
</def>
</def-item>
<def-item>
<term>MF</term>
<def>
<p>mycosis fungoides</p>
</def>
</def-item>
<def-item>
<term>NSAIDs</term>
<def>
<p>non-steroidal anti-inflammatory drugs</p>
</def>
</def-item>
<def-item>
<term>PSO</term>
<def>
<p>psoriasis</p>
</def>
</def-item>
<def-item>
<term>SC</term>
<def>
<p>scabies</p>
</def>
</def-item>
<def-item>
<term>SD</term>
<def>
<p>seborrheic dermatitis</p>
</def>
</def-item>
<def-item>
<term>SM</term>
<def>
<p>systemic mastocytosis</p>
</def>
</def-item>
<def-item>
<term>UD</term>
<def>
<p>urticarial dermatitis</p>
</def>
</def-item>
<def-item>
<term>UV</term>
<def>
<p>urticarial vasculitis</p>
</def>
</def-item>
</def-list>
</glossary>
<sec id="s8">
<title>Declarations</title>
<sec id="t-8-1">
<title>Author contributions</title>
<p>EC and M Perlato equally contributed to: Conceptualization, Data curation, Project administration, Supervision, Writing—original draft, Writing—review &amp; editing. EN, MC, and OR: Conceptualization, Writing—original draft. L Salvati, EDA, AR, DP, FA, RM, SM, NS, MT, LDB, M Passante, MDP, ADM, LP, LA, RC, IM, IT, MEC, SF, RG, AZ, EB, AB, DB, MN, MB, TDP, FG, CP, KH, FLF, IZ, ST, SG, CF, and L Stingeni: Writing—original draft. All authors read and approved the final version of the manuscript.</p>
</sec>
<sec id="t-8-2" sec-type="COI-statement">
<title>Conflicts of interest</title>
<p>The authors declare that they have no conflicts of interest.</p>
</sec>
<sec id="t-8-3">
<title>Ethical approval</title>
<p>Ethical approval was waived by the “AREA VASTA CENTRO” Ethics Committee since this is a scientific literature review.</p>
</sec>
<sec id="t-8-4">
<title>Consent to participate</title>
<p>The informed consent to participate in the study was obtained from relevant participants or the parents of relevant participants (under 16 years old).</p>
</sec>
<sec id="t-8-5">
<title>Consent to publication</title>
<p>The informed consent to publication was obtained from relevant participants or the parents of relevant participants (under 16 years old).</p>
</sec>
<sec id="t-8-6" sec-type="data-availability">
<title>Availability of data and materials</title>
<p>Not applicable.</p>
</sec>
<sec id="t-8-7">
<title>Funding</title>
<p>Not applicable.</p>
</sec>
<sec id="t-8-8">
<title>Copyright</title>
<p>© The Author(s) 2024.</p>
</sec>
</sec>
<ref-list>
<ref id="B1">
<label>1</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gravitz</surname>
<given-names>L</given-names>
</name>
</person-group>
<article-title>Skin</article-title>
<source>Nature</source>
<year iso-8601-date="2018">2018</year>
<volume>563</volume>
<elocation-id>S83</elocation-id>
<pub-id pub-id-type="doi">10.1038/d41586-018-07428-4</pub-id>
<pub-id pub-id-type="pmid">30464282</pub-id>
</element-citation>
</ref>
<ref id="B2">
<label>2</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bains</surname>
<given-names>SN</given-names>
</name>
<name>
<surname>Nash</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Fonacier</surname>
<given-names>L</given-names>
</name>
</person-group>
<article-title>Irritant Contact Dermatitis</article-title>
<source>Clin Rev Allergy Immunol</source>
<year iso-8601-date="2019">2019</year>
<volume>56</volume>
<fpage>99</fpage>
<lpage>109</lpage>
<pub-id pub-id-type="doi">10.1007/s12016-018-8713-0</pub-id>
<pub-id pub-id-type="pmid">30293200</pub-id>
</element-citation>
</ref>
<ref id="B3">
<label>3</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Adler</surname>
<given-names>BL</given-names>
</name>
<name>
<surname>DeLeo</surname>
<given-names>VA</given-names>
</name>
</person-group>
<article-title>Allergic Contact Dermatitis</article-title>
<source>JAMA Dermatol</source>
<year iso-8601-date="2021">2021</year>
<volume>157</volume>
<elocation-id>364</elocation-id>
<pub-id pub-id-type="doi">10.1001/jamadermatol.2020.5639</pub-id>
<pub-id pub-id-type="pmid">33502447</pub-id>
</element-citation>
</ref>
<ref id="B4">
<label>4</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Deleuran</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Vestergaard</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>Clinical heterogeneity and differential diagnosis of atopic dermatitis</article-title>
<source>Br J Dermatol</source>
<year iso-8601-date="2014">2014</year>
<volume>170</volume>
<fpage>2</fpage>
<lpage>6</lpage>
<pub-id pub-id-type="doi">10.1111/bjd.12933</pub-id>
<pub-id pub-id-type="pmid">24720512</pub-id>
</element-citation>
</ref>
<ref id="B5">
<label>5</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>So</surname>
<given-names>JK</given-names>
</name>
<name>
<surname>Hamstra</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Calame</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Hamann</surname>
<given-names>CR</given-names>
</name>
<name>
<surname>Jacob</surname>
<given-names>SE</given-names>
</name>
</person-group>
<article-title>Another Great Imitator: Allergic Contact Dermatitis Differential Diagnosis, Clues to Diagnosis, Histopathology, and Treatment</article-title>
<source>Curr Treat Options Allergy</source>
<year iso-8601-date="2015">2015</year>
<volume>2</volume>
<fpage>333</fpage>
<lpage>48</lpage>
<pub-id pub-id-type="doi">10.1007/s40521-015-0064-y</pub-id>
</element-citation>
</ref>
<ref id="B6">
<label>6</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pongpairoj</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Puangpet</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Thaiwat</surname>
<given-names>S</given-names>
</name>
<name>
<surname>McFadden</surname>
<given-names>JP</given-names>
</name>
</person-group>
<article-title>Diagnosing Allergic Contact Dermatitis Through Elimination, Perception, Detection and Deduction</article-title>
<source>Am J Clin Dermatol</source>
<year iso-8601-date="2017">2017</year>
<volume>18</volume>
<fpage>651</fpage>
<lpage>61</lpage>
<pub-id pub-id-type="doi">10.1007/s40257-017-0287-8</pub-id>
<pub-id pub-id-type="pmid">28508257</pub-id>
</element-citation>
</ref>
<ref id="B7">
<label>7</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Milam</surname>
<given-names>EC</given-names>
</name>
<name>
<surname>Jacob</surname>
<given-names>SE</given-names>
</name>
<name>
<surname>Cohen</surname>
<given-names>DE</given-names>
</name>
</person-group>
<article-title>Contact Dermatitis in the Patient with Atopic Dermatitis</article-title>
<source>J Allergy Clin Immunol Pract</source>
<year iso-8601-date="2019">2019</year>
<volume>7</volume>
<fpage>18</fpage>
<lpage>26</lpage>
<pub-id pub-id-type="doi">10.1016/j.jaip.2018.11.003</pub-id>
<pub-id pub-id-type="pmid">30598176</pub-id>
</element-citation>
</ref>
<ref id="B8">
<label>8</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schmidlin</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Sani</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Bernstein</surname>
<given-names>DI</given-names>
</name>
<name>
<surname>Fonacier</surname>
<given-names>L</given-names>
</name>
</person-group>
<article-title>A Hands-on Approach to Contact Dermatitis and Patch Testing</article-title>
<source>J Allergy Clin Immunol Pract</source>
<year iso-8601-date="2020">2020</year>
<volume>8</volume>
<fpage>1883</fpage>
<lpage>93</lpage>
<pub-id pub-id-type="doi">10.1016/j.jaip.2020.02.009</pub-id>
<pub-id pub-id-type="pmid">32112924</pub-id>
</element-citation>
</ref>
<ref id="B9">
<label>9</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yüksel</surname>
<given-names>YT</given-names>
</name>
<name>
<surname>Nørreslet</surname>
<given-names>LB</given-names>
</name>
<name>
<surname>Thyssen</surname>
<given-names>JP</given-names>
</name>
</person-group>
<article-title>Allergic Contact Dermatitis in Patients with Atopic Dermatitis</article-title>
<source>Curr Derm Rep</source>
<year iso-8601-date="2021">2021</year>
<volume>10</volume>
<fpage>67</fpage>
<lpage>76</lpage>
<pub-id pub-id-type="doi">10.1007/s13671-021-00335-4</pub-id>
</element-citation>
</ref>
<ref id="B10">
<label>10</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kovitwanichkanont</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Chong</surname>
<given-names>AH</given-names>
</name>
</person-group>
<article-title>Superficial fungal infections</article-title>
<source>Aust J Gen Pract</source>
<year iso-8601-date="2019">2019</year>
<volume>48</volume>
<fpage>706</fpage>
<lpage>11</lpage>
<pub-id pub-id-type="doi">10.31128/AJGP-05-19-4930</pub-id>
<pub-id pub-id-type="pmid">31569324</pub-id>
</element-citation>
</ref>
<ref id="B11">
<label>11</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Chamorro</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Syed</surname>
<given-names>HA</given-names>
</name>
<name>
<surname>House</surname>
<given-names>SA</given-names>
</name>
</person-group>
<source>Tinea Manuum</source>
<publisher-loc>Treasure Island (FL)</publisher-loc>
<publisher-name>StatPearls Publishing</publisher-name>
<year iso-8601-date="2024">2024</year>
<pub-id pub-id-type="pmid">32644474</pub-id>
</element-citation>
</ref>
<ref id="B12">
<label>12</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Errichetti</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Stinco</surname>
<given-names>G</given-names>
</name>
</person-group>
<article-title>Dermoscopy in tinea manuum</article-title>
<source>An Bras Dermatol</source>
<year iso-8601-date="2018">2018</year>
<volume>93</volume>
<fpage>447</fpage>
<lpage>8</lpage>
<pub-id pub-id-type="doi">10.1590/abd1806-4841.20186366</pub-id>
<pub-id pub-id-type="pmid">29924225</pub-id>
<pub-id pub-id-type="pmcid">PMC6001110</pub-id>
</element-citation>
</ref>
<ref id="B13">
<label>13</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Telner</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Fekete</surname>
<given-names>Z</given-names>
</name>
</person-group>
<article-title>The capillary responses in psoriatic skin</article-title>
<source>J Invest Dermatol</source>
<year iso-8601-date="1961">1961</year>
<volume>36</volume>
<fpage>225</fpage>
<lpage>30</lpage>
<pub-id pub-id-type="doi">10.1038/jid.1961.36</pub-id>
<pub-id pub-id-type="pmid">13775806</pub-id>
</element-citation>
</ref>
<ref id="B14">
<label>14</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pinkus</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Mehregan</surname>
<given-names>AH</given-names>
</name>
</person-group>
<article-title>The primary histologic lesion of seborrheic dermatitis and psoriasis</article-title>
<source>J Invest Dermatol</source>
<year iso-8601-date="1966">1966</year>
<volume>46</volume>
<fpage>109</fpage>
<lpage>16</lpage>
<pub-id pub-id-type="doi">10.1038/jid.1966.16</pub-id>
<pub-id pub-id-type="pmid">4222023</pub-id>
</element-citation>
</ref>
<ref id="B15">
<label>15</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schubert</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Christophers</surname>
<given-names>E</given-names>
</name>
</person-group>
<article-title>Mast cells and macrophages in early relapsing psoriasis</article-title>
<source>Arch Dermatol Res</source>
<year iso-8601-date="1985">1985</year>
<volume>277</volume>
<fpage>352</fpage>
<lpage>8</lpage>
<pub-id pub-id-type="doi">10.1007/BF00509232</pub-id>
<pub-id pub-id-type="pmid">4026377</pub-id>
</element-citation>
</ref>
<ref id="B16">
<label>16</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kolesnik</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Franke</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Lux</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Quist</surname>
<given-names>SR</given-names>
</name>
<name>
<surname>Gollnick</surname>
<given-names>HP</given-names>
</name>
</person-group>
<article-title>Eczema in Psoriatico: An Important Differential Diagnosis Between Chronic Allergic Contact Dermatitis and Psoriasis in Palmoplantar Localization</article-title>
<source>Acta Derm Venereol</source>
<year iso-8601-date="2018">2018</year>
<volume>98</volume>
<fpage>50</fpage>
<lpage>8</lpage>
<pub-id pub-id-type="doi">10.2340/00015555-2779</pub-id>
<pub-id pub-id-type="pmid">28853491</pub-id>
</element-citation>
</ref>
<ref id="B17">
<label>17</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Al-Mutairi</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Abdalla</surname>
<given-names>TO</given-names>
</name>
<name>
<surname>Nour</surname>
<given-names>TM</given-names>
</name>
</person-group>
<article-title>Resistant palmoplantar lesions in patients of psoriasis: evaluation of the causes and comparison of the frequency of delayed-type hypersensitivity in patients without palm and sole lesions</article-title>
<source>Med Princ Pract</source>
<year iso-8601-date="2014">2014</year>
<volume>23</volume>
<fpage>561</fpage>
<lpage>7</lpage>
<pub-id pub-id-type="doi">10.1159/000365573</pub-id>
<pub-id pub-id-type="pmid">25196021</pub-id>
<pub-id pub-id-type="pmcid">PMC5586935</pub-id>
</element-citation>
</ref>
<ref id="B18">
<label>18</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bangsgaard</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Engkilde</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Thyssen</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Linneberg</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Nielsen</surname>
<given-names>NH</given-names>
</name>
<name>
<surname>Menné</surname>
<given-names>T</given-names>
</name>
<etal>et al.</etal>
</person-group>
<article-title>Inverse relationship between contact allergy and psoriasis: results from a patient- and a population-based study</article-title>
<source>Br J Dermatol</source>
<year iso-8601-date="2009">2009</year>
<volume>161</volume>
<fpage>1119</fpage>
<lpage>23</lpage>
<pub-id pub-id-type="doi">10.1111/j.1365-2133.2009.09314.x</pub-id>
<pub-id pub-id-type="pmid">19624542</pub-id>
</element-citation>
</ref>
<ref id="B19">
<label>19</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Caca-Biljanovska</surname>
<given-names>N</given-names>
</name>
<name>
<surname>V’lckova-Laskoska</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Balabanova-Stefanova</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Grivceva-Panovska</surname>
<given-names>V</given-names>
</name>
</person-group>
<article-title>Frequency of delayed-type hypersensitivity to contact allergens in palmo-plantar psoriasis</article-title>
<source>Prilozi</source>
<year iso-8601-date="2005">2005</year>
<volume>26</volume>
<fpage>131</fpage>
<lpage>41</lpage>
<pub-id pub-id-type="pmid">16400235</pub-id>
</element-citation>
</ref>
<ref id="B20">
<label>20</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Malhotra</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Kaur</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Saraswat</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Kumar</surname>
<given-names>B</given-names>
</name>
</person-group>
<article-title>Frequency of patch-test positivity in patients with psoriasis: a prospective controlled study</article-title>
<source>Acta Derm Venereol</source>
<year iso-8601-date="2002">2002</year>
<volume>82</volume>
<fpage>432</fpage>
<lpage>5</lpage>
<pub-id pub-id-type="doi">10.1080/000155502762064566</pub-id>
<pub-id pub-id-type="pmid">12575849</pub-id>
</element-citation>
</ref>
<ref id="B21">
<label>21</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Quaranta</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Eyerich</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Knapp</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Nasorri</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Scarponi</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Mattii</surname>
<given-names>M</given-names>
</name>
<etal>et al.</etal>
</person-group>
<article-title>Allergic contact dermatitis in psoriasis patients: typical, delayed, and non-interacting</article-title>
<source>PLoS One</source>
<year iso-8601-date="2014">2014</year>
<volume>9</volume>
<elocation-id>e101814</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pone.0101814</pub-id>
<pub-id pub-id-type="pmid">25058585</pub-id>
<pub-id pub-id-type="pmcid">PMC4109932</pub-id>
</element-citation>
</ref>
<ref id="B22">
<label>22</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Naldi</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Rebora</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Seborrheic dermatitis</article-title>
<source>N Engl J Med</source>
<year iso-8601-date="2009">2009</year>
<volume>360</volume>
<fpage>387</fpage>
<lpage>96</lpage>
<pub-id pub-id-type="doi">10.1056/NEJMcp0806464</pub-id>
<pub-id pub-id-type="pmid">19164189</pub-id>
</element-citation>
</ref>
<ref id="B23">
<label>23</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dessinioti</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Katsambas</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Seborrheic dermatitis: etiology, risk factors, and treatments: facts and controversies</article-title>
<source>Clin Dermatol</source>
<year iso-8601-date="2013">2013</year>
<volume>31</volume>
<fpage>343</fpage>
<lpage>51</lpage>
<pub-id pub-id-type="doi">10.1016/j.clindermatol.2013.01.001</pub-id>
<pub-id pub-id-type="pmid">23806151</pub-id>
</element-citation>
</ref>
<ref id="B24">
<label>24</label>
<element-citation publication-type="book">
<person-group person-group-type="editor">
<name>
<surname>Kang</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Amagai</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Bruckner</surname>
<given-names>AL</given-names>
</name>
<name>
<surname>Enk</surname>
<given-names>AH</given-names>
</name>
<name>
<surname>Margolis</surname>
<given-names>DJ</given-names>
</name>
<name>
<surname>McMichael</surname>
<given-names>AJ</given-names>
</name>
<etal>et al.</etal>
</person-group>
<source>Fitzpatrick’s dermatology</source>
<comment>9th ed. McGraw-Hill Education; 2019.</comment>
</element-citation>
</ref>
<ref id="B25">
<label>25</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cohen</surname>
<given-names>B</given-names>
</name>
</person-group>
<article-title>Differential Diagnosis of Diaper Dermatitis</article-title>
<source>Clin Pediatr (Phila)</source>
<year iso-8601-date="2017">2017</year>
<volume>56</volume>
<fpage>16S</fpage>
<lpage>22S</lpage>
<pub-id pub-id-type="doi">10.1177/0009922817706982</pub-id>
<pub-id pub-id-type="pmid">28420251</pub-id>
</element-citation>
</ref>
<ref id="B26">
<label>26</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lofgren</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Warshaw</surname>
<given-names>EM</given-names>
</name>
</person-group>
<article-title>Dyshidrosis: epidemiology, clinical characteristics, and therapy</article-title>
<source>Dermatitis</source>
<year iso-8601-date="2006">2006</year>
<volume>17</volume>
<fpage>165</fpage>
<lpage>81</lpage>
<pub-id pub-id-type="doi">10.2310/6620.2006.05021</pub-id>
<pub-id pub-id-type="pmid">17150166</pub-id>
</element-citation>
</ref>
<ref id="B27">
<label>27</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Calle</surname>
<given-names>Sarmiento PM</given-names>
</name>
<name>
<surname>Chango</surname>
<given-names>Azanza JJ</given-names>
</name>
</person-group>
<article-title>Dyshidrotic Eczema: A Common Cause of Palmar Dermatitis</article-title>
<source>Cureus</source>
<year iso-8601-date="2020">2020</year>
<volume>12</volume>
<elocation-id>e10839</elocation-id>
<pub-id pub-id-type="doi">10.7759/cureus.10839</pub-id>
<pub-id pub-id-type="pmid">33173645</pub-id>
<pub-id pub-id-type="pmcid">PMC7647841</pub-id>
</element-citation>
</ref>
<ref id="B28">
<label>28</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Angelini</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Vena</surname>
<given-names>GA</given-names>
</name>
</person-group>
<source>Manuale di dermatologia</source>
<comment>Sociatá Editrice Universo; 1985.</comment>
</element-citation>
</ref>
<ref id="B29">
<label>29</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gangar</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Thiagarajan</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Veeraraghavan</surname>
<given-names>N</given-names>
</name>
</person-group>
<article-title>Pruritic Rash on the Hands and Feet</article-title>
<source>Am Fam Physician</source>
<year iso-8601-date="2018">2018</year>
<volume>98</volume>
<fpage>685</fpage>
<lpage>6</lpage>
<pub-id pub-id-type="pmid">30485041</pub-id>
</element-citation>
</ref>
<ref id="B30">
<label>30</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Murphy</surname>
<given-names>PB</given-names>
</name>
<name>
<surname>Atwater</surname>
<given-names>AR</given-names>
</name>
<name>
<surname>Mueller</surname>
<given-names>M</given-names>
</name>
</person-group>
<source>Allergic Contact Dermatitis</source>
<publisher-loc>Treasure Island (FL)</publisher-loc>
<publisher-name>StatPearls Publishing</publisher-name>
<year iso-8601-date="2024">2024</year>
<pub-id pub-id-type="pmid">30422461</pub-id>
</element-citation>
</ref>
<ref id="B31">
<label>31</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Langan</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Irvine</surname>
<given-names>AD</given-names>
</name>
<name>
<surname>Weidinger</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Atopic dermatitis</article-title>
<source>Lancet</source>
<year iso-8601-date="2020">2020</year>
<volume>396</volume>
<fpage>345</fpage>
<lpage>60</lpage>
<pub-id pub-id-type="doi">10.1016/S0140-6736(20)31286-1</pub-id>
<pub-id pub-id-type="pmid">32738956</pub-id>
</element-citation>
</ref>
<ref id="B32">
<label>32</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ständer</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Atopic Dermatitis</article-title>
<source>N Engl J Med</source>
<year iso-8601-date="2021">2021</year>
<volume>384</volume>
<fpage>1136</fpage>
<lpage>43</lpage>
<pub-id pub-id-type="doi">10.1056/NEJMra2023911</pub-id>
<pub-id pub-id-type="pmid">33761208</pub-id>
</element-citation>
</ref>
<ref id="B33">
<label>33</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Barrett</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Luu</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Differential Diagnosis of Atopic Dermatitis</article-title>
<source>Immunol Allergy Clin North Am</source>
<year iso-8601-date="2017">2017</year>
<volume>37</volume>
<fpage>11</fpage>
<lpage>34</lpage>
<pub-id pub-id-type="doi">10.1016/j.iac.2016.08.009</pub-id>
<pub-id pub-id-type="pmid">27886900</pub-id>
</element-citation>
</ref>
<ref id="B34">
<label>34</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Griffiths</surname>
<given-names>CEM</given-names>
</name>
<name>
<surname>Armstrong</surname>
<given-names>AW</given-names>
</name>
<name>
<surname>Gudjonsson</surname>
<given-names>JE</given-names>
</name>
<name>
<surname>Barker</surname>
<given-names>JNWN</given-names>
</name>
</person-group>
<article-title>Psoriasis</article-title>
<source>Lancet</source>
<year iso-8601-date="2021">2021</year>
<volume>397</volume>
<fpage>1301</fpage>
<lpage>15</lpage>
<pub-id pub-id-type="doi">10.1016/S0140-6736(20)32549-6</pub-id>
<pub-id pub-id-type="pmid">33812489</pub-id>
</element-citation>
</ref>
<ref id="B35">
<label>35</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ji</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Bao</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Ruan</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>J</given-names>
</name>
<etal>et al.</etal>
</person-group>
<article-title>Challenge of Nail Psoriasis: An Update Review</article-title>
<source>Clin Rev Allergy Immunol</source>
<year iso-8601-date="2021">2021</year>
<volume>61</volume>
<fpage>377</fpage>
<lpage>402</lpage>
<pub-id pub-id-type="doi">10.1007/s12016-021-08896-9</pub-id>
<pub-id pub-id-type="pmid">34478047</pub-id>
</element-citation>
</ref>
<ref id="B36">
<label>36</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Engelman</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Yoshizumi</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Hay</surname>
<given-names>RJ</given-names>
</name>
<name>
<surname>Osti</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Micali</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Norton</surname>
<given-names>S</given-names>
</name>
<etal>et al.</etal>
</person-group>
<article-title>The 2020 International Alliance for the Control of Scabies Consensus Criteria for the Diagnosis of Scabies</article-title>
<source>Br J Dermatol</source>
<year iso-8601-date="2020">2020</year>
<volume>183</volume>
<fpage>808</fpage>
<lpage>20</lpage>
<pub-id pub-id-type="doi">10.1111/bjd.18943</pub-id>
<pub-id pub-id-type="pmid">32034956</pub-id>
<pub-id pub-id-type="pmcid">PMC7687112</pub-id>
</element-citation>
</ref>
<ref id="B37">
<label>37</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Willemze</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Cerroni</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Kempf</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Berti</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Facchetti</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Swerdlow</surname>
<given-names>SH</given-names>
</name>
<etal>et al.</etal>
</person-group>
<article-title>The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas</article-title>
<source>Blood</source>
<year iso-8601-date="2019">2019</year>
<volume>133</volume>
<fpage>1703</fpage>
<lpage>14</lpage>
<pub-id pub-id-type="doi">10.1182/blood-2018-11-881268</pub-id>
<pub-id pub-id-type="pmid">30635287</pub-id>
<pub-id pub-id-type="pmcid">PMC6473500</pub-id>
</element-citation>
</ref>
<ref id="B38">
<label>38</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Krol</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Krafchik</surname>
<given-names>B</given-names>
</name>
</person-group>
<article-title>The differential diagnosis of atopic dermatitis in childhood</article-title>
<source>Dermatol Ther</source>
<year iso-8601-date="2006">2006</year>
<volume>19</volume>
<fpage>73</fpage>
<lpage>82</lpage>
<pub-id pub-id-type="doi">10.1111/j.1529-8019.2006.00058.x</pub-id>
<pub-id pub-id-type="pmid">16669989</pub-id>
</element-citation>
</ref>
<ref id="B39">
<label>39</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Cerroni</surname>
<given-names>L</given-names>
</name>
</person-group>
<source>Skin Lymphoma: The Illustrated Guide</source>
<comment>5th ed. John Wiley &amp; Sons; 2020.</comment>
</element-citation>
</ref>
<ref id="B40">
<label>40</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Silverberg</surname>
<given-names>JI</given-names>
</name>
</person-group>
<article-title>Adult-Onset Atopic Dermatitis</article-title>
<source>J Allergy Clin Immunol Pract</source>
<year iso-8601-date="2019">2019</year>
<volume>7</volume>
<fpage>28</fpage>
<lpage>33</lpage>
<pub-id pub-id-type="doi">10.1016/j.jaip.2018.09.029</pub-id>
<pub-id pub-id-type="pmid">30598180</pub-id>
</element-citation>
</ref>
<ref id="B41">
<label>41</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Saulite</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Hoetzenecker</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Weidinger</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Cozzio</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Guenova</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Wehkamp</surname>
<given-names>U</given-names>
</name>
</person-group>
<article-title>Sézary Syndrome and Atopic Dermatitis: Comparison of Immunological Aspects and Targets</article-title>
<source>Biomed Res Int</source>
<year iso-8601-date="2016">2016</year>
<volume>2016</volume>
<elocation-id>9717530</elocation-id>
<pub-id pub-id-type="doi">10.1155/2016/9717530</pub-id>
<pub-id pub-id-type="pmid">27294147</pub-id>
<pub-id pub-id-type="pmcid">PMC4886049</pub-id>
</element-citation>
</ref>
<ref id="B42">
<label>42</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sidiropoulou</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Nikolaou</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Marinos</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Voudouri</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Komini</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Economidi</surname>
<given-names>A</given-names>
</name>
<etal>et al.</etal>
</person-group>
<article-title>The different faces of mycosis fungoides: results of a single-center study</article-title>
<source>Int J Dermatol</source>
<year iso-8601-date="2020">2020</year>
<volume>59</volume>
<fpage>314</fpage>
<lpage>20</lpage>
<pub-id pub-id-type="doi">10.1111/ijd.14735</pub-id>
<pub-id pub-id-type="pmid">31782525</pub-id>
</element-citation>
</ref>
<ref id="B43">
<label>43</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Willemze</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>Mycosis fungoides variants-clinicopathologic features, differential diagnosis, and treatment</article-title>
<source>Semin Cutan Med Surg</source>
<year iso-8601-date="2018">2018</year>
<volume>37</volume>
<fpage>11</fpage>
<lpage>7</lpage>
<pub-id pub-id-type="doi">10.12788/j.sder.2018.004</pub-id>
<pub-id pub-id-type="pmid">29719015</pub-id>
</element-citation>
</ref>
<ref id="B44">
<label>44</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zackheim</surname>
<given-names>HS</given-names>
</name>
<name>
<surname>McCalmont</surname>
<given-names>TH</given-names>
</name>
</person-group>
<article-title>Mycosis fungoides: the great imitator</article-title>
<source>J Am Acad Dermatol</source>
<year iso-8601-date="2002">2002</year>
<volume>47</volume>
<fpage>914</fpage>
<lpage>8</lpage>
<pub-id pub-id-type="doi">10.1067/mjd.2002.124696</pub-id>
<pub-id pub-id-type="pmid">12451378</pub-id>
</element-citation>
</ref>
<ref id="B45">
<label>45</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nashan</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Faulhaber</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Ständer</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Luger</surname>
<given-names>TA</given-names>
</name>
<name>
<surname>Stadler</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>Mycosis fungoides: a dermatological masquerader</article-title>
<source>Br J Dermatol</source>
<year iso-8601-date="2007">2007</year>
<volume>156</volume>
<fpage>1</fpage>
<lpage>10</lpage>
<pub-id pub-id-type="doi">10.1111/j.1365-2133.2006.07526.x</pub-id>
<pub-id pub-id-type="pmid">17199560</pub-id>
</element-citation>
</ref>
<ref id="B46">
<label>46</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Miyagaki</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Sugaya</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Erythrodermic cutaneous T-cell lymphoma: how to differentiate this rare disease from atopic dermatitis</article-title>
<source>J Dermatol Sci</source>
<year iso-8601-date="2011">2011</year>
<volume>64</volume>
<fpage>1</fpage>
<lpage>6</lpage>
<pub-id pub-id-type="doi">10.1016/j.jdermsci.2011.07.007</pub-id>
<pub-id pub-id-type="pmid">21872448</pub-id>
</element-citation>
</ref>
<ref id="B47">
<label>47</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mistry</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Gupta</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Alavi</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Sibbald</surname>
<given-names>RG</given-names>
</name>
</person-group>
<article-title>A review of the diagnosis and management of erythroderma (generalized red skin)</article-title>
<source>Adv Skin Wound Care</source>
<year iso-8601-date="2015">2015</year>
<volume>28</volume>
<fpage>228</fpage>
<lpage>36</lpage>
<pub-id pub-id-type="doi">10.1097/01.ASW.0000463573.40637.73</pub-id>
<pub-id pub-id-type="pmid">25882661</pub-id>
</element-citation>
</ref>
<ref id="B48">
<label>48</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>O’Connell</surname>
<given-names>KA</given-names>
</name>
<name>
<surname>LaChance</surname>
<given-names>AH</given-names>
</name>
</person-group>
<article-title>Dermatomyositis</article-title>
<source>N Engl J Med</source>
<year iso-8601-date="2021">2021</year>
<volume>384</volume>
<elocation-id>2437</elocation-id>
<pub-id pub-id-type="doi">10.1056/NEJMicm2033425</pub-id>
<pub-id pub-id-type="pmid">34161709</pub-id>
</element-citation>
</ref>
<ref id="B49">
<label>49</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bailey</surname>
<given-names>EE</given-names>
</name>
<name>
<surname>Fiorentino</surname>
<given-names>DF</given-names>
</name>
</person-group>
<article-title>Amyopathic dermatomyositis: definitions, diagnosis, and management</article-title>
<source>Curr Rheumatol Rep</source>
<year iso-8601-date="2014">2014</year>
<volume>16</volume>
<elocation-id>465</elocation-id>
<pub-id pub-id-type="doi">10.1007/s11926-014-0465-0</pub-id>
<pub-id pub-id-type="pmid">25366932</pub-id>
</element-citation>
</ref>
<ref id="B50">
<label>50</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Horiuchi</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>Hereditary Angioedema from 1888 to 2018 -Progress and Problems</article-title>
<source>Intern Med</source>
<year iso-8601-date="2018">2018</year>
<volume>57</volume>
<fpage>3065</fpage>
<lpage>6</lpage>
<pub-id pub-id-type="doi">10.2169/internalmedicine.1818-18</pub-id>
<pub-id pub-id-type="pmid">30210137</pub-id>
<pub-id pub-id-type="pmcid">PMC6262708</pub-id>
</element-citation>
</ref>
<ref id="B51">
<label>51</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bork</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Wulff</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Witzke</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Hardt</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Hereditary angioedema with normal C1-INH with <italic>versus</italic> without specific <italic>F12</italic> gene mutations</article-title>
<source>Allergy</source>
<year iso-8601-date="2015">2015</year>
<volume>70</volume>
<fpage>1004</fpage>
<lpage>12</lpage>
<pub-id pub-id-type="doi">10.1111/all.12648</pub-id>
<pub-id pub-id-type="pmid">25952149</pub-id>
</element-citation>
</ref>
<ref id="B52">
<label>52</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Busse</surname>
<given-names>PJ</given-names>
</name>
<name>
<surname>Christiansen</surname>
<given-names>SC</given-names>
</name>
</person-group>
<article-title>Hereditary Angioedema</article-title>
<source>N Engl J Med</source>
<year iso-8601-date="2020">2020</year>
<volume>382</volume>
<fpage>1136</fpage>
<lpage>48</lpage>
<pub-id pub-id-type="doi">10.1056/NEJMra1808012</pub-id>
<pub-id pub-id-type="pmid">32187470</pub-id>
</element-citation>
</ref>
<ref id="B53">
<label>53</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bork</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Hardt</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Witzke</surname>
<given-names>G</given-names>
</name>
</person-group>
<article-title>Fatal laryngeal attacks and mortality in hereditary angioedema due to C1-INH deficiency</article-title>
<source>J Allergy Clin Immunol</source>
<year iso-8601-date="2012">2012</year>
<volume>130</volume>
<fpage>692</fpage>
<lpage>7</lpage>
<pub-id pub-id-type="doi">10.1016/j.jaci.2012.05.055</pub-id>
<pub-id pub-id-type="pmid">22841766</pub-id>
</element-citation>
</ref>
<ref id="B54">
<label>54</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Maurer</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Magerl</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Betschel</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Aberer</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Ansotegui</surname>
<given-names>IJ</given-names>
</name>
<name>
<surname>Aygören-Pürsün</surname>
<given-names>E</given-names>
</name>
<etal>et al.</etal>
</person-group>
<article-title>The international WAO/EAACI guideline for the management of hereditary angioedema—The 2021 revision and update</article-title>
<source>Allergy</source>
<year iso-8601-date="2022">2022</year>
<volume>77</volume>
<fpage>1961</fpage>
<lpage>90</lpage>
<pub-id pub-id-type="doi">10.1111/all.15214</pub-id>
<pub-id pub-id-type="pmid">35006617</pub-id>
</element-citation>
</ref>
<ref id="B55">
<label>55</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rubinstein</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Stolz</surname>
<given-names>LE</given-names>
</name>
<name>
<surname>Sheffer</surname>
<given-names>AL</given-names>
</name>
<name>
<surname>Stevens</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Bousvaros</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Abdominal attacks and treatment in hereditary angioedema with C1-inhibitor deficiency</article-title>
<source>BMC Gastroenterol</source>
<year iso-8601-date="2014">2014</year>
<volume>14</volume>
<elocation-id>71</elocation-id>
<pub-id pub-id-type="doi">10.1186/1471-230X-14-71</pub-id>
<pub-id pub-id-type="pmid">24712435</pub-id>
<pub-id pub-id-type="pmcid">PMC4101849</pub-id>
</element-citation>
</ref>
<ref id="B56">
<label>56</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jalaj</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Scolapio</surname>
<given-names>JS</given-names>
</name>
</person-group>
<article-title>Gastrointestinal manifestations, diagnosis, and management of hereditary angioedema</article-title>
<source>J Clin Gastroenterol</source>
<year iso-8601-date="2013">2013</year>
<volume>47</volume>
<fpage>817</fpage>
<lpage>23</lpage>
<pub-id pub-id-type="doi">10.1097/MCG.0b013e31829e7edf</pub-id>
<pub-id pub-id-type="pmid">24141983</pub-id>
</element-citation>
</ref>
<ref id="B57">
<label>57</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Obtułowicz</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Stobiecki</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Dyga</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Juchacz</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Popiela</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Obtułowicz</surname>
<given-names>K</given-names>
</name>
</person-group>
<article-title>Abdominal and pelvic imaging in the diagnosis of acute abdominal attacks in patients with hereditary angioedema due to C1-inhibitor deficiency</article-title>
<source>Postepy Dermatol Alergol</source>
<year iso-8601-date="2022">2022</year>
<volume>39</volume>
<fpage>749</fpage>
<lpage>56</lpage>
<pub-id pub-id-type="doi">10.5114/ada.2021.108438</pub-id>
<pub-id pub-id-type="pmid">36090726</pub-id>
<pub-id pub-id-type="pmcid">PMC9454366</pub-id>
</element-citation>
</ref>
<ref id="B58">
<label>58</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bova</surname>
<given-names>M</given-names>
</name>
<name>
<surname>De</surname>
<given-names>Feo G</given-names>
</name>
<name>
<surname>Parente</surname>
<given-names>R</given-names>
</name>
<name>
<surname>De</surname>
<given-names>Pasquale T</given-names>
</name>
<name>
<surname>Gravante</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Pucci</surname>
<given-names>S</given-names>
</name>
<etal>et al.</etal>
</person-group>
<article-title>Hereditary and Acquired Angioedema: Heterogeneity of Pathogenesis and Clinical Phenotypes</article-title>
<source>Int Arch Allergy Immunol</source>
<year iso-8601-date="2018">2018</year>
<volume>175</volume>
<fpage>126</fpage>
<lpage>35</lpage>
<pub-id pub-id-type="doi">10.1159/000486312</pub-id>
<pub-id pub-id-type="pmid">29393169</pub-id>
</element-citation>
</ref>
<ref id="B59">
<label>59</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Manning</surname>
<given-names>ME</given-names>
</name>
</person-group>
<article-title>Hereditary angioedema: Differential diagnosis, diagnostic tests, and family screening</article-title>
<source>Allergy Asthma Proc</source>
<year iso-8601-date="2020">2020</year>
<volume>41</volume>
<fpage>S22</fpage>
<lpage>5</lpage>
<pub-id pub-id-type="doi">10.2500/aap.2020.41.200062</pub-id>
<pub-id pub-id-type="pmid">33109321</pub-id>
</element-citation>
</ref>
<ref id="B60">
<label>60</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Inomata</surname>
<given-names>N</given-names>
</name>
</person-group>
<article-title>Recent advances in drug-induced angioedema</article-title>
<source>Allergol Int</source>
<year iso-8601-date="2012">2012</year>
<volume>61</volume>
<fpage>545</fpage>
<lpage>57</lpage>
<pub-id pub-id-type="doi">10.2332/allergolint.12-RAI-0493</pub-id>
<pub-id pub-id-type="pmid">23183389</pub-id>
</element-citation>
</ref>
<ref id="B61">
<label>61</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Marceau</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Hess</surname>
<given-names>JF</given-names>
</name>
<name>
<surname>Bachvarov</surname>
<given-names>DR</given-names>
</name>
</person-group>
<article-title>The B1 receptors for kinins</article-title>
<source>Pharmacol Rev</source>
<year iso-8601-date="1998">1998</year>
<volume>50</volume>
<fpage>357</fpage>
<lpage>86</lpage>
<pub-id pub-id-type="pmid">9755287</pub-id>
</element-citation>
</ref>
<ref id="B62">
<label>62</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kostis</surname>
<given-names>WJ</given-names>
</name>
<name>
<surname>Shetty</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Chowdhury</surname>
<given-names>YS</given-names>
</name>
<name>
<surname>Kostis</surname>
<given-names>JB</given-names>
</name>
</person-group>
<article-title>ACE Inhibitor-Induced Angioedema: a Review</article-title>
<source>Curr Hypertens Rep</source>
<year iso-8601-date="2018">2018</year>
<volume>20</volume>
<elocation-id>55</elocation-id>
<pub-id pub-id-type="doi">10.1007/s11906-018-0859-x</pub-id>
<pub-id pub-id-type="pmid">29884969</pub-id>
</element-citation>
</ref>
<ref id="B63">
<label>63</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Miller</surname>
<given-names>DR</given-names>
</name>
<name>
<surname>Oliveria</surname>
<given-names>SA</given-names>
</name>
<name>
<surname>Berlowitz</surname>
<given-names>DR</given-names>
</name>
<name>
<surname>Fincke</surname>
<given-names>BG</given-names>
</name>
<name>
<surname>Stang</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Lillienfeld</surname>
<given-names>DE</given-names>
</name>
</person-group>
<article-title>Angioedema incidence in US veterans initiating angiotensin-converting enzyme inhibitors</article-title>
<source>Hypertension</source>
<year iso-8601-date="2008">2008</year>
<volume>51</volume>
<fpage>1624</fpage>
<lpage>30</lpage>
<pub-id pub-id-type="doi">10.1161/HYPERTENSIONAHA.108.110270</pub-id>
<pub-id pub-id-type="pmid">18413488</pub-id>
</element-citation>
</ref>
<ref id="B64">
<label>64</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Abdi</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Dong</surname>
<given-names>VM</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>CJ</given-names>
</name>
<name>
<surname>Ntoso</surname>
<given-names>KA</given-names>
</name>
</person-group>
<article-title>Angiotensin II receptor blocker-associated angioedema: on the heels of ACE inhibitor angioedema</article-title>
<source>Pharmacotherapy</source>
<year iso-8601-date="2002">2002</year>
<volume>22</volume>
<fpage>1173</fpage>
<lpage>5</lpage>
<pub-id pub-id-type="doi">10.1592/phco.22.13.1173.33517</pub-id>
<pub-id pub-id-type="pmid">12222553</pub-id>
</element-citation>
</ref>
<ref id="B65">
<label>65</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mansi</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Zanichelli</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Coerezza</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Suffritti</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Vacchini</surname>
<given-names>R</given-names>
</name>
<etal>et al.</etal>
</person-group>
<article-title>Presentation, diagnosis and treatment of angioedema without wheals: a retrospective analysis of a cohort of 1058 patients</article-title>
<source>J Intern Med</source>
<year iso-8601-date="2015">2015</year>
<volume>277</volume>
<fpage>585</fpage>
<lpage>93</lpage>
<pub-id pub-id-type="doi">10.1111/joim.12304</pub-id>
<pub-id pub-id-type="pmid">25196353</pub-id>
</element-citation>
</ref>
<ref id="B66">
<label>66</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cicardi</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Aberer</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Banerji</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Bas</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Bernstein</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Bork</surname>
<given-names>K</given-names>
</name>
<etal>et al.</etal>
<collab>HAWK under the patronage of EAACI (European Academy of Allergy and Clinical Immunology)</collab>
</person-group>
<article-title>Classification, diagnosis, and approach to treatment for angioedema: consensus report from the Hereditary Angioedema International Working Group</article-title>
<source>Allergy</source>
<year iso-8601-date="2014">2014</year>
<volume>69</volume>
<fpage>602</fpage>
<lpage>16</lpage>
<pub-id pub-id-type="doi">10.1111/all.12380</pub-id>
<pub-id pub-id-type="pmid">24673465</pub-id>
</element-citation>
</ref>
<ref id="B67">
<label>67</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gülbahar</surname>
<given-names>O</given-names>
</name>
</person-group>
<article-title>Angioedema without wheals: a clinical update</article-title>
<source>Balkan Med J</source>
<year iso-8601-date="2021">2021</year>
<volume>38</volume>
<fpage>73</fpage>
<lpage>81</lpage>
<pub-id pub-id-type="doi">10.5152/balkanmedj.2021.20060</pub-id>
<pub-id pub-id-type="pmid">33593719</pub-id>
<pub-id pub-id-type="pmcid">PMC8909242</pub-id>
</element-citation>
</ref>
<ref id="B68">
<label>68</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Faisant</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Boccon-Gibod</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Mansard</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Dumestre</surname>
<given-names>Perard C</given-names>
</name>
<name>
<surname>Pralong</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Chatain</surname>
<given-names>C</given-names>
</name>
<etal>et al.</etal>
</person-group>
<article-title>Idiopathic histaminergic angioedema without wheals: a case series of 31 patients</article-title>
<source>Clin Exp Immunol</source>
<year iso-8601-date="2016">2016</year>
<volume>185</volume>
<fpage>81</fpage>
<lpage>5</lpage>
<pub-id pub-id-type="doi">10.1111/cei.12789</pub-id>
<pub-id pub-id-type="pmid">26969870</pub-id>
<pub-id pub-id-type="pmcid">PMC4908297</pub-id>
</element-citation>
</ref>
<ref id="B69">
<label>69</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Perego</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Zanichelli</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Cicardi</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Angioedema Phenotypes: Disease Expression and Classification</article-title>
<source>Clin Rev Allergy Immunol</source>
<year iso-8601-date="2016">2016</year>
<volume>51</volume>
<fpage>162</fpage>
<lpage>9</lpage>
<pub-id pub-id-type="doi">10.1007/s12016-016-8541-z</pub-id>
<pub-id pub-id-type="pmid">27113957</pub-id>
</element-citation>
</ref>
<ref id="B70">
<label>70</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zuberbier</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Aberer</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Asero</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Abdul</surname>
<given-names>Latiff AH</given-names>
</name>
<name>
<surname>Baker</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Ballmer-Weber</surname>
<given-names>B</given-names>
</name>
<etal>et al.</etal>
<collab>Endorsed by the following societies: AAAAI, AAD, AAIITO, ACAAI, AEDV, APAAACI, ASBAI, ASCIA, BAD, BSACI, CDA, CMICA, CSACI, DDG, DDS, DGAKI, DSA, DST, EAACI, EIAS, EDF, EMBRN, ESCD, GA<sup>2</sup>LEN, IAACI, IADVL, JDA, NVvA, MSAI, ÖGDV, PSA, RAACI, SBD, SFD, SGAI, SGDV, SIAAIC, SIDeMaST, SPDV, TSD, UNBB, UNEV and WAO</collab>
</person-group>
<article-title>The EAACI/GA<sup>2</sup>LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria</article-title>
<source>Allergy</source>
<year iso-8601-date="2018">2018</year>
<volume>73</volume>
<fpage>1393</fpage>
<lpage>414</lpage>
<pub-id pub-id-type="doi">10.1111/all.13397</pub-id>
<pub-id pub-id-type="pmid">29336054</pub-id>
</element-citation>
</ref>
<ref id="B71">
<label>71</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>He</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Yi</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Long</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>Q</given-names>
</name>
</person-group>
<article-title>Chronic Urticaria: Advances in Understanding of the Disease and Clinical Management</article-title>
<source>Clin Rev Allergy Immunol</source>
<year iso-8601-date="2021">2021</year>
<volume>61</volume>
<fpage>424</fpage>
<lpage>48</lpage>
<pub-id pub-id-type="doi">10.1007/s12016-021-08886-x</pub-id>
<pub-id pub-id-type="pmid">34529248</pub-id>
</element-citation>
</ref>
<ref id="B72">
<label>72</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kossard</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Hamann</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Wilkinson</surname>
<given-names>B</given-names>
</name>
</person-group>
<article-title>Defining urticarial dermatitis: a subset of dermal hypersensitivity reaction pattern</article-title>
<source>Arch Dermatol</source>
<year iso-8601-date="2006">2006</year>
<volume>142</volume>
<fpage>29</fpage>
<lpage>34</lpage>
<pub-id pub-id-type="doi">10.1001/archderm.142.1.29</pub-id>
<pub-id pub-id-type="pmid">16415383</pub-id>
</element-citation>
</ref>
<ref id="B73">
<label>73</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Byth</surname>
<given-names>LA</given-names>
</name>
</person-group>
<article-title>Urticarial dermatitis: a nosological dilemma</article-title>
<source>Int J Dermatol</source>
<year iso-8601-date="2019">2019</year>
<volume>58</volume>
<fpage>e196</fpage>
<lpage>8</lpage>
<pub-id pub-id-type="doi">10.1111/ijd.14545</pub-id>
<pub-id pub-id-type="pmid">31183855</pub-id>
</element-citation>
</ref>
<ref id="B74">
<label>74</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hannon</surname>
<given-names>GR</given-names>
</name>
<name>
<surname>Wetter</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Gibson</surname>
<given-names>LE</given-names>
</name>
</person-group>
<article-title>Urticarial dermatitis: clinical features, diagnostic evaluation, and etiologic associations in a series of 146 patients at Mayo Clinic (2006-2012)</article-title>
<source>J Am Acad Dermatol</source>
<year iso-8601-date="2014">2014</year>
<volume>70</volume>
<fpage>263</fpage>
<lpage>8</lpage>
<pub-id pub-id-type="doi">10.1016/j.jaad.2013.08.050</pub-id>
<pub-id pub-id-type="pmid">24268310</pub-id>
</element-citation>
</ref>
<ref id="B75">
<label>75</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kim</surname>
<given-names>TI</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>HJ</given-names>
</name>
<name>
<surname>Won</surname>
<given-names>YY</given-names>
</name>
<name>
<surname>Choi</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Jeong</surname>
<given-names>KH</given-names>
</name>
<name>
<surname>Sung</surname>
<given-names>JY</given-names>
</name>
<etal>et al.</etal>
</person-group>
<article-title>Basement Membrane Status Is Intact in Urticarial Dermatitis vs. Adult-Onset Atopic Dermatitis</article-title>
<source>Ann Dermatol</source>
<year iso-8601-date="2018">2018</year>
<volume>30</volume>
<fpage>258</fpage>
<lpage>61</lpage>
<pub-id pub-id-type="doi">10.5021/ad.2018.30.2.258</pub-id>
<pub-id pub-id-type="pmid">29606837</pub-id>
<pub-id pub-id-type="pmcid">PMC5839911</pub-id>
</element-citation>
</ref>
<ref id="B76">
<label>76</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ben</surname>
<given-names>Kridis W</given-names>
</name>
<name>
<surname>Khanfir</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>An uncommon case of pancreatic adenocarcinoma revealed by dermatitis</article-title>
<source>JGH Open</source>
<year iso-8601-date="2022">2022</year>
<volume>6</volume>
<fpage>280</fpage>
<lpage>1</lpage>
<pub-id pub-id-type="doi">10.1002/jgh3.12734</pub-id>
<pub-id pub-id-type="pmid">35475197</pub-id>
<pub-id pub-id-type="pmcid">PMC9021705</pub-id>
</element-citation>
</ref>
<ref id="B77">
<label>77</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Banan</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Butler</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Retrospective chart review in a cohort of patients with urticarial dermatitis</article-title>
<source>Australas J Dermatol</source>
<year iso-8601-date="2014">2014</year>
<volume>55</volume>
<fpage>137</fpage>
<lpage>9</lpage>
<pub-id pub-id-type="doi">10.1111/ajd.12088</pub-id>
<pub-id pub-id-type="pmid">23808754</pub-id>
</element-citation>
</ref>
<ref id="B78">
<label>78</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Radhakrishnan</surname>
<given-names>RC</given-names>
</name>
<name>
<surname>Basu</surname>
<given-names>G</given-names>
</name>
<name>
<surname>George</surname>
<given-names>RE</given-names>
</name>
<name>
<surname>Parmar</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Tamilarasi</surname>
<given-names>V</given-names>
</name>
</person-group>
<article-title>Rituximab-induced urticarial dermatitis during the treatment of membranous nephropathy</article-title>
<source>Saudi J Kidney Dis Transpl</source>
<year iso-8601-date="2017">2017</year>
<volume>28</volume>
<fpage>657</fpage>
<lpage>60</lpage>
<pub-id pub-id-type="doi">10.4103/1319-2442.206462</pub-id>
<pub-id pub-id-type="pmid">28540910</pub-id>
</element-citation>
</ref>
<ref id="B79">
<label>79</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ikediobi</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Eichenfield</surname>
<given-names>DZ</given-names>
</name>
<name>
<surname>Barrio</surname>
<given-names>VR</given-names>
</name>
</person-group>
<article-title>Eosinophilic cellulitis in response to BNT162b2 COVID-19 vaccination</article-title>
<source>Pediatr Dermatol</source>
<year iso-8601-date="2022">2022</year>
<volume>39</volume>
<fpage>823</fpage>
<lpage>4</lpage>
<pub-id pub-id-type="doi">10.1111/pde.15019</pub-id>
<pub-id pub-id-type="pmid">35522122</pub-id>
<pub-id pub-id-type="pmcid">PMC9347735</pub-id>
</element-citation>
</ref>
<ref id="B80">
<label>80</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mata</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Lian</surname>
<given-names>JW</given-names>
</name>
<name>
<surname>Krakowski</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Agarwala</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Hafeez</surname>
<given-names>F</given-names>
</name>
</person-group>
<article-title>Histopathologic and immunophenotypic features of idiopathic dermal hypersensitivity reaction/urticarial dermatitis: A clinicopathologic study</article-title>
<source>J Cutan Pathol</source>
<year iso-8601-date="2021">2021</year>
<volume>48</volume>
<fpage>592</fpage>
<lpage>5</lpage>
<pub-id pub-id-type="doi">10.1111/cup.13884</pub-id>
<pub-id pub-id-type="pmid">32979279</pub-id>
</element-citation>
</ref>
<ref id="B81">
<label>81</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nguyen</surname>
<given-names>CN</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>SJ</given-names>
</name>
</person-group>
<article-title>Dermatitis Herpetiformis: An Update on Diagnosis, Disease Monitoring, and Management</article-title>
<source>Medicina (Kaunas)</source>
<year iso-8601-date="2021">2021</year>
<volume>57</volume>
<elocation-id>843</elocation-id>
<pub-id pub-id-type="doi">10.3390/medicina57080843</pub-id>
<pub-id pub-id-type="pmid">34441049</pub-id>
<pub-id pub-id-type="pmcid">PMC8400185</pub-id>
</element-citation>
</ref>
<ref id="B82">
<label>82</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Reunala</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Salmi</surname>
<given-names>TT</given-names>
</name>
<name>
<surname>Hervonen</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Kaukinen</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Collin</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>Dermatitis Herpetiformis: A Common Extraintestinal Manifestation of Coeliac Disease</article-title>
<source>Nutrients</source>
<year iso-8601-date="2018">2018</year>
<volume>10</volume>
<elocation-id>602</elocation-id>
<pub-id pub-id-type="doi">10.3390/nu10050602</pub-id>
<pub-id pub-id-type="pmid">29757210</pub-id>
<pub-id pub-id-type="pmcid">PMC5986482</pub-id>
</element-citation>
</ref>
<ref id="B83">
<label>83</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Antiga</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Maglie</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Quintarelli</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Verdelli</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Bonciani</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Bonciolini</surname>
<given-names>V</given-names>
</name>
<etal>et al.</etal>
</person-group>
<article-title>Dermatitis Herpetiformis: Novel Perspectives</article-title>
<source>Front Immunol</source>
<year iso-8601-date="2019">2019</year>
<volume>10</volume>
<elocation-id>1290</elocation-id>
<pub-id pub-id-type="doi">10.3389/fimmu.2019.01290</pub-id>
<pub-id pub-id-type="pmid">31244841</pub-id>
<pub-id pub-id-type="pmcid">PMC6579917</pub-id>
</element-citation>
</ref>
<ref id="B84">
<label>84</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ohshima</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Tamada</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Matsumoto</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Hashimoto</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>Dermatitis herpetiformis Duhring with palmoplantar keratosis</article-title>
<source>Br J Dermatol</source>
<year iso-8601-date="2003">2003</year>
<volume>149</volume>
<fpage>1300</fpage>
<lpage>2</lpage>
<pub-id pub-id-type="doi">10.1111/j.1365-2133.2003.05660.x</pub-id>
<pub-id pub-id-type="pmid">14674919</pub-id>
</element-citation>
</ref>
<ref id="B85">
<label>85</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Holtmeier</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Pfänder</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Zollner</surname>
<given-names>TM</given-names>
</name>
<name>
<surname>Kaufmann</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Caspary</surname>
<given-names>WF</given-names>
</name>
</person-group>
<article-title>Distinct TCR δ repertoires are present in the cutaneous lesions and inflamed duodenum of patients with dermatitis herpetiformis</article-title>
<source>Exp Dermatol</source>
<year iso-8601-date="2002">2002</year>
<volume>11</volume>
<fpage>527</fpage>
<lpage>31</lpage>
<pub-id pub-id-type="doi">10.1034/j.1600-0625.2002.110605.x</pub-id>
<pub-id pub-id-type="pmid">12473060</pub-id>
</element-citation>
</ref>
<ref id="B86">
<label>86</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zone</surname>
<given-names>JJ</given-names>
</name>
<name>
<surname>Meyer</surname>
<given-names>LJ</given-names>
</name>
<name>
<surname>Petersen</surname>
<given-names>MJ</given-names>
</name>
</person-group>
<article-title>Deposition of granular IgA relative to clinical lesions in dermatitis herpetiformis</article-title>
<source>Arch Dermatol</source>
<year iso-8601-date="1996">1996</year>
<volume>132</volume>
<fpage>912</fpage>
<lpage>8</lpage>
<pub-id pub-id-type="doi">10.1001/archderm.1996.03890320060010</pub-id>
<pub-id pub-id-type="pmid">8712841</pub-id>
</element-citation>
</ref>
<ref id="B87">
<label>87</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Görög</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Antiga</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Caproni</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Cianchini</surname>
<given-names>G</given-names>
</name>
<name>
<surname>De</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Dmochowski</surname>
<given-names>M</given-names>
</name>
<etal>et al.</etal>
</person-group>
<article-title>S2k guidelines (consensus statement) for diagnosis and therapy of dermatitis herpetiformis initiated by the European Academy of Dermatology and Venereology (EADV)</article-title>
<source>J Eur Acad Dermatol Venereol</source>
<year iso-8601-date="2021">2021</year>
<volume>35</volume>
<fpage>1251</fpage>
<lpage>77</lpage>
<pub-id pub-id-type="doi">10.1111/jdv.17183</pub-id>
<pub-id pub-id-type="pmid">34004067</pub-id>
</element-citation>
</ref>
<ref id="B88">
<label>88</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Borroni</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Biagi</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Ciocca</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Vassallo</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Carugno</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Cananzi</surname>
<given-names>R</given-names>
</name>
<etal>et al.</etal>
</person-group>
<article-title>IgA anti-epidermal transglutaminase autoantibodies: a sensible and sensitive marker for diagnosis of dermatitis herpetiformis in adult patients</article-title>
<source>J Eur Acad Dermatol Venereol</source>
<year iso-8601-date="2013">2013</year>
<volume>27</volume>
<fpage>836</fpage>
<lpage>41</lpage>
<pub-id pub-id-type="doi">10.1111/j.1468-3083.2012.04586.x</pub-id>
<pub-id pub-id-type="pmid">22672004</pub-id>
</element-citation>
</ref>
<ref id="B89">
<label>89</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Parker</surname>
<given-names>SR</given-names>
</name>
<name>
<surname>MacKelfresh</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Autoimmune blistering diseases in the elderly</article-title>
<source>Clin Dermatol</source>
<year iso-8601-date="2011">2011</year>
<volume>29</volume>
<fpage>69</fpage>
<lpage>79</lpage>
<pub-id pub-id-type="doi">10.1016/j.clindermatol.2010.07.010</pub-id>
<pub-id pub-id-type="pmid">21146735</pub-id>
</element-citation>
</ref>
<ref id="B90">
<label>90</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Moro</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Fania</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Sinagra</surname>
<given-names>JLM</given-names>
</name>
<name>
<surname>Salemme</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Di</surname>
<given-names>Zenzo G</given-names>
</name>
</person-group>
<article-title>Bullous Pemphigoid: Trigger and Predisposing Factors</article-title>
<source>Biomolecules</source>
<year iso-8601-date="2020">2020</year>
<volume>10</volume>
<elocation-id>1432</elocation-id>
<pub-id pub-id-type="doi">10.3390/biom10101432</pub-id>
<pub-id pub-id-type="pmid">33050407</pub-id>
<pub-id pub-id-type="pmcid">PMC7600534</pub-id>
</element-citation>
</ref>
<ref id="B91">
<label>91</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schmidt</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Goebeler</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Hertl</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Sárdy</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Sitaru</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Eming</surname>
<given-names>R</given-names>
</name>
<etal>et al.</etal>
</person-group>
<article-title>S2k guideline for the diagnosis of pemphigus vulgaris/foliaceus and bullous pemphigoid</article-title>
<source>J Dtsch Dermatol Ges</source>
<year iso-8601-date="2015">2015</year>
<volume>13</volume>
<fpage>713</fpage>
<lpage>27</lpage>
<pub-id pub-id-type="doi">10.1111/ddg.12612</pub-id>
<pub-id pub-id-type="pmid">26110729</pub-id>
</element-citation>
</ref>
<ref id="B92">
<label>92</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Genovese</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Di</surname>
<given-names>Zenzo G</given-names>
</name>
<name>
<surname>Cozzani</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Berti</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Cugno</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Marzano</surname>
<given-names>AV</given-names>
</name>
</person-group>
<article-title>New Insights Into the Pathogenesis of Bullous Pemphigoid: 2019 Update</article-title>
<source>Front Immunol</source>
<year iso-8601-date="2019">2019</year>
<volume>10</volume>
<elocation-id>1506</elocation-id>
<pub-id pub-id-type="doi">10.3389/fimmu.2019.01506</pub-id>
<pub-id pub-id-type="pmid">31312206</pub-id>
<pub-id pub-id-type="pmcid">PMC6614376</pub-id>
</element-citation>
</ref>
<ref id="B93">
<label>93</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ruggiero</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Megna</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Villani</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Comune</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Fabbrocini</surname>
<given-names>G</given-names>
</name>
<name>
<surname>di Vico</surname>
<given-names>F</given-names>
</name>
</person-group>
<article-title>Strategies to Improve Outcomes of Bullous Pemphigoid: A Comprehensive Review of Clinical Presentations, Diagnosis, and Patients’ Assessment</article-title>
<source>Clin Cosmet Investig Dermatol</source>
<year iso-8601-date="2022">2022</year>
<volume>15</volume>
<fpage>661</fpage>
<lpage>73</lpage>
<pub-id pub-id-type="doi">10.2147/CCID.S267573</pub-id>
<pub-id pub-id-type="pmid">35444441</pub-id>
<pub-id pub-id-type="pmcid">PMC9014958</pub-id>
</element-citation>
</ref>
<ref id="B94">
<label>94</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hamad</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Jithpratuck</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Krishnaswamy</surname>
<given-names>G</given-names>
</name>
</person-group>
<article-title>Urticarial vasculitis and associated disorders</article-title>
<source>Ann Allergy Asthma Immunol</source>
<year iso-8601-date="2017">2017</year>
<volume>118</volume>
<fpage>394</fpage>
<lpage>8</lpage>
<pub-id pub-id-type="doi">10.1016/j.anai.2017.01.017</pub-id>
<pub-id pub-id-type="pmid">28390580</pub-id>
</element-citation>
</ref>
<ref id="B95">
<label>95</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jachiet</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Flageul</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Deroux</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Le</surname>
<given-names>Quellec A</given-names>
</name>
<name>
<surname>Maurier</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Cordoliani</surname>
<given-names>F</given-names>
</name>
<etal>et al.</etal>
<collab>French Vasculitis Study Group</collab>
</person-group>
<article-title>The clinical spectrum and therapeutic management of hypocomplementemic urticarial vasculitis: data from a French nationwide study of fifty-seven patients</article-title>
<source>Arthritis Rheumatol</source>
<year iso-8601-date="2015">2015</year>
<volume>67</volume>
<fpage>527</fpage>
<lpage>34</lpage>
<pub-id pub-id-type="doi">10.1002/art.38956</pub-id>
<pub-id pub-id-type="pmid">25385679</pub-id>
</element-citation>
</ref>
<ref id="B96">
<label>96</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kolkhir</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Grakhova</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Bonnekoh</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Krause</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Maurer</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Treatment of urticarial vasculitis: A systematic review</article-title>
<source>J Allergy Clin Immunol</source>
<year iso-8601-date="2019">2019</year>
<volume>143</volume>
<fpage>458</fpage>
<lpage>66</lpage>
<pub-id pub-id-type="doi">10.1016/j.jaci.2018.09.007</pub-id>
<pub-id pub-id-type="pmid">30268388</pub-id>
</element-citation>
</ref>
<ref id="B97">
<label>97</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kamyab</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Ghodsi</surname>
<given-names>SZ</given-names>
</name>
<name>
<surname>Ghanadan</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Taghizadeh</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Karimi</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Nasimi</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Eosinophilic infiltration: an under-reported histological finding in urticarial vasculitis</article-title>
<source>Int J Dermatol</source>
<year iso-8601-date="2019">2019</year>
<volume>58</volume>
<fpage>825</fpage>
<lpage>9</lpage>
<pub-id pub-id-type="doi">10.1111/ijd.14387</pub-id>
<pub-id pub-id-type="pmid">30693472</pub-id>
</element-citation>
</ref>
<ref id="B98">
<label>98</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Arber</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Orazi</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Hasserjian</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Thiele</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Borowitz</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Le</surname>
<given-names>Beau MM</given-names>
</name>
<etal>et al.</etal>
</person-group>
<article-title>The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia</article-title>
<source>Blood</source>
<year iso-8601-date="2016">2016</year>
<volume>127</volume>
<fpage>2391</fpage>
<lpage>405</lpage>
<pub-id pub-id-type="doi">10.1182/blood-2016-03-643544</pub-id>
<pub-id pub-id-type="pmid">27069254</pub-id>
</element-citation>
</ref>
<ref id="B99">
<label>99</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pardanani</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Systemic mastocytosis in adults: 2021 Update on diagnosis, risk stratification and management</article-title>
<source>Am J Hematol</source>
<year iso-8601-date="2021">2021</year>
<volume>96</volume>
<fpage>508</fpage>
<lpage>25</lpage>
<pub-id pub-id-type="doi">10.1002/ajh.26118</pub-id>
<pub-id pub-id-type="pmid">33524167</pub-id>
</element-citation>
</ref>
<ref id="B100">
<label>100</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Di</surname>
<given-names>Raimondo C</given-names>
</name>
<name>
<surname>Del</surname>
<given-names>Duca E</given-names>
</name>
<name>
<surname>Silvaggio</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Di</surname>
<given-names>Prete M</given-names>
</name>
<name>
<surname>Lombardo</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Mazzeo</surname>
<given-names>M</given-names>
</name>
<etal>et al.</etal>
</person-group>
<article-title>Cutaneous mastocytosis: A dermatological perspective</article-title>
<source>Australas J Dermatol</source>
<year iso-8601-date="2021">2021</year>
<volume>62</volume>
<fpage>e1</fpage>
<lpage>7</lpage>
<pub-id pub-id-type="doi">10.1111/ajd.13443</pub-id>
<pub-id pub-id-type="pmid">33040350</pub-id>
</element-citation>
</ref>
<ref id="B101">
<label>101</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Valent</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Escribano</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Broesby-Olsen</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Hartmann</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Grattan</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Brockow</surname>
<given-names>K</given-names>
</name>
<etal>et al.</etal>
<collab>European Competence Network on Mastocytosis</collab>
</person-group>
<article-title>Proposed diagnostic algorithm for patients with suspected mastocytosis: a proposal of the European Competence Network on Mastocytosis</article-title>
<source>Allergy</source>
<year iso-8601-date="2014">2014</year>
<volume>69</volume>
<fpage>1267</fpage>
<lpage>74</lpage>
<pub-id pub-id-type="doi">10.1111/all.12436</pub-id>
<pub-id pub-id-type="pmid">24836395</pub-id>
</element-citation>
</ref>
<ref id="B102">
<label>102</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lyons</surname>
<given-names>JJ</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Hughes</surname>
<given-names>JD</given-names>
</name>
<name>
<surname>Le</surname>
<given-names>QT</given-names>
</name>
<name>
<surname>Jamil</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Bai</surname>
<given-names>Y</given-names>
</name>
<etal>et al.</etal>
</person-group>
<article-title>Elevated basal serum tryptase identifies a multisystem disorder associated with increased <italic>TPSAB1</italic> copy number</article-title>
<source>Nat Genet</source>
<year iso-8601-date="2016">2016</year>
<volume>48</volume>
<fpage>1564</fpage>
<lpage>9</lpage>
<pub-id pub-id-type="doi">10.1038/ng.3696</pub-id>
<pub-id pub-id-type="pmid">27749843</pub-id>
<pub-id pub-id-type="pmcid">PMC5397297</pub-id>
</element-citation>
</ref>
<ref id="B103">
<label>103</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Luskin</surname>
<given-names>KT</given-names>
</name>
<name>
<surname>White</surname>
<given-names>AA</given-names>
</name>
<name>
<surname>Lyons</surname>
<given-names>JJ</given-names>
</name>
</person-group>
<article-title>The Genetic Basis and Clinical Impact of Hereditary Alpha-Tryptasemia</article-title>
<source>J Allergy Clin Immunol Pract</source>
<year iso-8601-date="2021">2021</year>
<volume>9</volume>
<fpage>2235</fpage>
<lpage>42</lpage>
<pub-id pub-id-type="doi">10.1016/j.jaip.2021.03.005</pub-id>
<pub-id pub-id-type="pmid">33744473</pub-id>
</element-citation>
</ref>
<ref id="B104">
<label>104</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sprinzl</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Greiner</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Uyanik</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Arock</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Haferlach</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Sperr</surname>
<given-names>WR</given-names>
</name>
<etal>et al.</etal>
</person-group>
<article-title>Genetic Regulation of Tryptase Production and Clinical Impact: Hereditary Alpha Tryptasemia, Mastocytosis and Beyond</article-title>
<source>Int J Mol Sci</source>
<year iso-8601-date="2021">2021</year>
<volume>22</volume>
<elocation-id>2458</elocation-id>
<pub-id pub-id-type="doi">10.3390/ijms22052458</pub-id>
<pub-id pub-id-type="pmid">33671092</pub-id>
<pub-id pub-id-type="pmcid">PMC7957558</pub-id>
</element-citation>
</ref>
<ref id="B105">
<label>105</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lyons</surname>
<given-names>JJ</given-names>
</name>
</person-group>
<article-title>Hereditary Alpha Tryptasemia: Genotyping and Associated Clinical Features</article-title>
<source>Immunol Allergy Clin North Am</source>
<year iso-8601-date="2018">2018</year>
<volume>38</volume>
<fpage>483</fpage>
<lpage>95</lpage>
<pub-id pub-id-type="doi">10.1016/j.iac.2018.04.003</pub-id>
<pub-id pub-id-type="pmid">30007465</pub-id>
<pub-id pub-id-type="pmcid">PMC6411063</pub-id>
</element-citation>
</ref>
<ref id="B106">
<label>106</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Robey</surname>
<given-names>RC</given-names>
</name>
<name>
<surname>Wilcock</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Bonin</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Beaman</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Myers</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Grattan</surname>
<given-names>C</given-names>
</name>
<etal>et al.</etal>
</person-group>
<article-title>Hereditary Alpha-Tryptasemia: UK Prevalence and Variability in Disease Expression</article-title>
<source>J Allergy Clin Immunol Pract</source>
<year iso-8601-date="2020">2020</year>
<volume>8</volume>
<fpage>3549</fpage>
<lpage>56</lpage>
<pub-id pub-id-type="doi">10.1016/j.jaip.2020.05.057</pub-id>
<pub-id pub-id-type="pmid">32553831</pub-id>
</element-citation>
</ref>
<ref id="B107">
<label>107</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lyons</surname>
<given-names>JJ</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Stone</surname>
<given-names>KD</given-names>
</name>
<name>
<surname>Nelson</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Wisch</surname>
<given-names>L</given-names>
</name>
<name>
<surname>O’Brien</surname>
<given-names>M</given-names>
</name>
<etal>et al.</etal>
</person-group>
<article-title>Mendelian inheritance of elevated serum tryptase associated with atopy and connective tissue abnormalities</article-title>
<source>J Allergy Clin Immunol</source>
<year iso-8601-date="2014">2014</year>
<volume>133</volume>
<fpage>1471</fpage>
<lpage>4</lpage>
<pub-id pub-id-type="doi">10.1016/j.jaci.2013.11.039</pub-id>
<pub-id pub-id-type="pmid">24472624</pub-id>
<pub-id pub-id-type="pmcid">PMC4016972</pub-id>
</element-citation>
</ref>
<ref id="B108">
<label>108</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Greiner</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Sprinzl</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Górska</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Ratzinger</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Gurbisz</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Witzeneder</surname>
<given-names>N</given-names>
</name>
<etal>et al.</etal>
</person-group>
<article-title>Hereditary α tryptasemia is a valid genetic biomarker for severe mediator-related symptoms in mastocytosis</article-title>
<source>Blood</source>
<year iso-8601-date="2021">2021</year>
<volume>137</volume>
<fpage>238</fpage>
<lpage>47</lpage>
<pub-id pub-id-type="doi">10.1182/blood.2020006157</pub-id>
<pub-id pub-id-type="pmid">32777817</pub-id>
<pub-id pub-id-type="pmcid">PMC7116780</pub-id>
</element-citation>
</ref>
<ref id="B109">
<label>109</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Glover</surname>
<given-names>SC</given-names>
</name>
<name>
<surname>Carter</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Korošec</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Bonadonna</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Schwartz</surname>
<given-names>LB</given-names>
</name>
<name>
<surname>Milner</surname>
<given-names>JD</given-names>
</name>
<etal>et al.</etal>
</person-group>
<article-title>Clinical relevance of inherited genetic differences in human tryptases: Hereditary alpha-tryptasemia and beyond</article-title>
<source>Ann Allergy Asthma Immunol</source>
<year iso-8601-date="2021">2021</year>
<volume>127</volume>
<fpage>638</fpage>
<lpage>47</lpage>
<pub-id pub-id-type="doi">10.1016/j.anai.2021.08.009</pub-id>
<pub-id pub-id-type="pmid">34400315</pub-id>
<pub-id pub-id-type="pmcid">PMC9413800</pub-id>
</element-citation>
</ref>
</ref-list>
</back>
</article>